Report Sections

See All Reports

  • HP:0002664: Neoplasm
  • Pneumonia (361) Abnormality of the cardiovascular system (36) Respiratory tract infection (36) Neoplasm (29) Hypoxemia (28) Diabetes mellitus (25) Depressivity (24) Thromboembolism (23) Acute kidney injury (22) Abnormal lung morphology (21) Anosmia (19) Hypertension (18) Abnormality of coagulation (15) Pulmonary embolism (15) Pulmonary fibrosis (15) Stroke (14) Arthritis (14) Interstitial pneumonitis (14) Myocardial infarction (12) Type II diabetes mellitus (12) Deep venous thrombosis (11) Rheumatoid arthritis (10) Leukemia (10) Respiratory distress (10) Low levels of vitamin D (10) Behavioral abnormality (9) Mental deterioration (9) Chronic pain (9) Congestive heart failure (8) Myocarditis (8) Type I diabetes mellitus (8) Sepsis (8) Infertility (7) Abnormality of the liver (7) Lymphopenia (7) Inflammation of the large intestine (7) Pulmonary obstruction (7) Pulmonary insufficiency (7) Immunodeficiency (6) Systemic lupus erythematosus (6) Chronic pulmonary obstruction (6) Abnormality of the gastrointestinal tract (6) Neoplasm of the lung (6) Encephalopathy (5) Obesity (5) Lymphoma (5) Autoimmunity (5) Breast carcinoma (5) Disseminated intravascular coagulation (5) Fatigue (5) Abnormality of the kidney (4) Coronary artery atherosclerosis (4) Cardiac arrest (4) Headache (4) Colon cancer (4) Arrhythmia (4) Carcinoma (4) Hypercoagulability (4) Autistic behavior (3) Seizure (3) Cardiomyopathy (3) Dysphagia (3) Migraine (3) Pulmonary arterial hypertension (3) Asthma (3) Bronchiectasis (3) Neoplasm of the pancreas (3) Psoriasiform dermatitis (3) Attention deficit hyperactivity disorder (3) Cutaneous melanoma (3) Neoplasm of head and neck (3) Pulmonary edema (3) Insomnia (3) Neoplasm of the large intestine (3) Renal insufficiency (2) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Psychosis (2) Autism (2) Dementia (2) Abnormality of the endocrine system (2) Abnormality of the thyroid gland (2) Jaundice (2) Hepatic fibrosis (2) Premature birth (2) Abnormal heart morphology (2) Abnormality of blood and blood-forming tissues (2) Fever (2) Diarrhea (2) Hypothermia (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Encephalitis (2) Obstructive sleep apnea (2) Male infertility (2) Stillbirth (2) Paroxysmal atrial fibrillation (2) Lymphoid leukemia (2) Myeloproliferative disorder (2) Chronic lymphatic leukemia (2) Renal cell carcinoma (2) Multiple myeloma (2) Abnormal anterior horn cell morphology (2) Amyotrophic lateral sclerosis (2) Sleep apnea (2) Cystoid macular edema (2) Hemeralopia (2) Arteritis (2) Chronic kidney disease (2) Cervix cancer (2) Cholangitis (2) Cholangiocarcinoma (2) Myositis (2) Neuroendocrine neoplasm (2) Neoplasm of the rectum (2) Mania (2) Nephritis (1) Menorrhagia (1) Conductive hearing impairment (1) Cataract (1) Amblyopia (1) Periodontitis (1) Abnormality of the nervous system (1) Oligospermia (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Abnormality of the skin (1) Lymphedema (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Spastic diplegia (1) Hemiparesis (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Tachycardia (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Angina pectoris (1) Pancreatitis (1) Premature rupture of membranes (1) Weight loss (1) Thrombocytopenia (1) Autoimmune thrombocytopenia (1) Gastroesophageal reflux (1) Anorexia (1) Esophageal varix (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Hyperkinetic movements (1) Alzheimer disease (1) Increased intracranial pressure (1) Colitis (1) Biliary cirrhosis (1) Hypotension (1) Vascular dilatation (1) Atherosclerosis (1) Osteoarthritis (1) Tachypnea (1) Hypoventilation (1) Myelodysplasia (1) Neoplasm of the liver (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Reduced factor VIII activity (1) Skeletal muscle atrophy (1) Myalgia (1) Muscular dystrophy (1) Neonatal death (1) Increased body weight (1) Neoplasm of the nervous system (1) Malnutrition (1) Thrombophlebitis (1) Ventricular tachycardia (1) Acute myeloid leukemia (1) Dilatation of the cerebral artery (1) Knee osteoarthritis (1) Monoclonal immunoglobulin M proteinemia (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the stomach (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Renal neoplasm (1) Uterine neoplasm (1) Testicular neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Inflammatory abnormality of the skin (1) Placental abruption (1) Postprandial hyperglycemia (1) Endometrial carcinoma (1) Erythroid hypoplasia (1) Asterixis (1) Glioblastoma multiforme (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Morphea (1) Allergy (1) Non-Hodgkin lymphoma (1) Retinal vein occlusion (1) Heart block (1) Dyspareunia (1) Ductal carcinoma in situ (1) Endometriosis (1) Cardiogenic shock (1) Vulvar neoplasm (1) Addictive behavior (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Neoplasm of the central nervous system (1) Abnormality of movement (1) Ulcerative colitis (1) Crohn's disease (1) Endocarditis (1) Toxemia of pregnancy (1) Neoplasm of the larynx (1) Ovarian neoplasm (1) Vaginal neoplasm (1) Cellulitis (1) Bulimia (1) Atelectasis (1) Esophageal neoplasm (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0002664: Neoplasm

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (39)


    Name (Synonyms) Correlation
    drug2672 Quality-of-Life Assessment Wiki 0.28
    drug2687 Questionnaire Administration Wiki 0.27
    drug415 Best Practice Wiki 0.25
    Name (Synonyms) Correlation
    drug2409 Peripheral venous ultrasound Wiki 0.19
    drug338 Azithromycin 250 MG Oral Capsule Wiki 0.19
    drug3333 Therapeutic Exercise and Education Wiki 0.19
    drug2828 Rintatolimod Wiki 0.19
    drug3022 Serology SARS-CoV2 Wiki 0.19
    drug2469 Placebo Administration Wiki 0.19
    drug2670 Quality of life assessment Wiki 0.19
    drug2252 Obvio-19 app Wiki 0.19
    drug2911 SCH Intervention Wiki 0.19
    drug1686 Intubation Box Wiki 0.19
    drug614 COVID-19 diagnostic test Wiki 0.19
    drug2759 Recombinant Interferon Alfa-2b Wiki 0.19
    drug3603 Web-based REDCap survey Wiki 0.19
    drug170 Aerosol Box Wiki 0.19
    drug2353 PT-PCR test for SARS-CoV-2 Wiki 0.19
    drug3248 TAK-981 Wiki 0.19
    drug3877 modification of the planned therapeutic management Wiki 0.19
    drug729 Chemotherapy Wiki 0.19
    drug1274 Fenofibrate Wiki 0.19
    drug3219 Survey Administration Wiki 0.19
    drug1293 Flow cytometric analysis Wiki 0.13
    drug1768 Leflunomide Wiki 0.13
    drug967 Data Collection Wiki 0.13
    drug1497 Hydroxychloroquine Sulfate 200 MG [Plaquenil] Wiki 0.13
    drug2512 Placebo oral capsule Wiki 0.11
    drug3505 Usual care Wiki 0.11
    drug1566 Ibrutinib Wiki 0.11
    drug377 BNT162b2 Wiki 0.09
    drug453 Biospecimen Collection Wiki 0.09
    drug1818 Lopinavir/Ritonavir Wiki 0.09
    drug969 Data collection Wiki 0.08
    drug3976 questionnaire Wiki 0.06
    drug3375 Tocilizumab Wiki 0.06
    drug3146 Standard of care Wiki 0.04
    drug2514 Placebo oral tablet Wiki 0.03
    drug2448 Placebo Wiki 0.02

    Correlated MeSH Terms (27)


    Name (Synonyms) Correlation
    D009369 Neoplasms, NIH 0.98
    D019337 Hematologic Neoplasms NIH 0.28
    D010051 Ovarian Neoplasms NIH 0.19
    Name (Synonyms) Correlation
    D000741 Anemia, Aplastic NIH 0.19
    D014594 Uterine Neoplasms NIH 0.19
    D014625 Vaginal Neoplasms NIH 0.19
    D010265 Paraproteinemias NIH 0.19
    D008998 Monoclonal Gammopathy of Undetermined Significance NIH 0.19
    D014846 Vulvar Neoplasms NIH 0.19
    D008218 Lymphocytosis NIH 0.19
    D002583 Uterine Cervical Neoplasms NIH 0.13
    D009190 Myelodysplastic Syndromes NIH 0.13
    D009196 Myeloproliferative Disorders NIH 0.11
    D003324 Coronary Artery Disease NIH 0.09
    D001943 Breast Neoplasms NIH 0.08
    D007676 Kidney Failure, Chronic NIH 0.08
    D029424 Pulmonary Disease, Chronic Obstructive NIH 0.08
    D008173 Lung Diseases, Obstructive NIH 0.07
    D020521 Stroke NIH 0.05
    D013923 Thromboembolism NIH 0.04
    D007239 Infection NIH 0.03
    D012127 Respiratory Distress Syndrome, Newborn NIH 0.02
    D055371 Acute Lung Injury NIH 0.02
    D012128 Respiratory Distress Syndrome, Adult NIH 0.01
    D003141 Communicable Diseases NIH 0.01
    D011014 Pneumonia NIH 0.01
    D018352 Coronavirus Infections NIH 0.01

    Correlated HPO Terms (17)


    Name (Synonyms) Correlation
    HP:0001909 Leukemia HPO 0.23
    HP:0100650 Vaginal neoplasm HPO 0.19
    HP:0030416 Vulvar neoplasm HPO 0.19
    Name (Synonyms) Correlation
    HP:0100827 Lymphocytosis HPO 0.19
    HP:0012133 Erythroid hypoplasia HPO 0.19
    HP:0100615 Ovarian neoplasm HPO 0.19
    HP:0010784 Uterine neoplasm HPO 0.19
    HP:0002863 Myelodysplasia HPO 0.19
    HP:0005547 Myeloproliferative disorder HPO 0.13
    HP:0030079 Cervix cancer HPO 0.13
    HP:0001677 Coronary artery atherosclerosis HPO 0.09
    HP:0003002 Breast carcinoma HPO 0.08
    HP:0006510 Chronic pulmonary obstruction HPO 0.08
    HP:0006536 Pulmonary obstruction HPO 0.07
    HP:0001297 Stroke HPO 0.05
    HP:0001907 Thromboembolism HPO 0.04
    HP:0002090 Pneumonia HPO 0.01

    Clinical Trials

    Navigate: Correlations   HPO

    There are 29 clinical trials


    1 An Open Label, Dose-Escalation, Phase I Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of TAK-981 in Adult Patients With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019

    The primary objective of this study is to determine the safety and tolerability of TAK-981 as a single agent in participants with advanced or metastatic solid tumors and lymphomas in Phase 1, to evaluate preliminary efficacy of TAK-981 in participants with select solid tumors or relapsed/refractory CD20-positive (CD20+) non-hodgkin lymphoma (NHL) indications in Phase 2, and to assess change in severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) viral load within 8 days of TAK-981 administration in COVID-19 Expansion.

    NCT03648372
    Conditions
    1. Neoplasms
    2. Lymphoma
    3. Hematologic Neoplasms
    4. Coronavirus Disease
    Interventions
    1. Drug: TAK-981
    2. Drug: Standard of care
    MeSH:Coronavirus Infections Neoplasms Hematologic Neoplasms
    HPO:Hematological neoplasm Leukemia Neoplasm

    Primary Outcomes

    Measure: Phase 1: Number of Participants Reporting one or More Treatment Emergent Adverse Events (TEAEs)

    Time: Up to 48 months

    Description: Severity grade will be evaluated as per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0, except for Cytokine Release Syndrome (CRS), which will be assessed by American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading criteria.

    Measure: Phase 1: Number of Participants Based on Severity of TEAEs

    Time: Up to 48 months

    Measure: Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)

    Time: Up to Cycle 1 (Cycle length is equal to [=] 21 days)

    Measure: Phase 1: Number of Participants With Clinically Significant Laboratory Values

    Time: Up to 48 months

    Description: ORR is defined as percentage of participants who achieve complete response (CR) and partial response (PR), as determined by the investigator according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST V1.1) for participants with solid tumors or Lugano classification for lymphoma.

    Measure: Phase 2: Overall Response Rate (ORR)

    Time: From the first dose until best response is achieved (up to 4 years)

    Measure: COVID-19 Expansion: Number of Participants With Greater Than or Equal to (>=) 2 log Reduction From Baseline in Viral Load or Below Level of Detection (Negative) in Nasopharyngeal or Oropharyngeal Samples

    Time: Up to 9 months

    Secondary Outcomes

    Measure: Phase 2: Number of Participants Reporting one or More TEAEs

    Time: Up to 48 months

    Description: Severity grade will be evaluated as per the NCI CTCAE Version 5.0, except for CRS, which will be assessed by ASTCT consensus grading criteria.

    Measure: Phase 2: Number of Participants Based on Severity of TEAEs

    Time: Up to 48 months

    Measure: Phase 2, Cmax: Maximum Observed Plasma Concentration for TAK-981

    Time: Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post dose; Cycle 1 Day 8 pre-dose and at multiple time points (up to 24 hours) post dose (Cycle length is equal to [=] 21 days)

    Measure: Phase 2, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-981

    Time: Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post dose; Cycle 1 Day 8 pre-dose and at multiple time points (up to 24 hours) post dose (Cycle length =21 days)

    Measure: Phase 2, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-981

    Time: Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post dose; Cycle 1 Day 8 pre-dose and at multiple time points (up to 24 hours) post dose (Cycle length =21 days)

    Measure: Phase 2, AUC∞: Area Under the Plasma Concentration-time Curve from Time 0 to Infinity for TAK-981

    Time: Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post dose; Cycle 1 Day 8 pre-dose and at multiple time points (up to 24 hours) post dose (Cycle length =21 days)

    Measure: Phase 2, Terminal Disposition Phase Half-life (t1/2z) for TAK-981

    Time: Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post dose; Cycle 1 Day 8 pre-dose and at multiple time points (up to 24 hours) post dose (Cycle length =21 days)

    Measure: Phase 2, Total Clearance (CL) After Intravenous Administration for TAK-981

    Time: Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post dose; Cycle 1 Day 8 pre-dose and at multiple time points (up to 24 hours) post dose (Cycle length =21 days)

    Measure: Phase 2, Volume of Distribution at Steady State After Intravenous Administration (Vss) for TAK-981

    Time: Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post dose; Cycle 1 Day 8 pre-dose and at multiple time points (up to 24 hours) post dose (Cycle length =21 days)

    Description: ORR is defined as percentage of participants who achieve CR and PR through the study (approximately 4 years), as determined by the investigator according to the RECIST V1.1 for participants with solid tumors or Lugano classification for lymphoma.

    Measure: Phase 2: ORR

    Time: From the first dose until best response is achieved (up to 4 years)

    Description: DOR is the time from the date of first documentation of a PR or better to the date of first documentation of progressive disease for responders (PR or better) and will be determined by the investigator according to RECIST v1.1 for participants with solid tumors or Lugano classification for lymphoma.

    Measure: Phase 2: Duration of Response (DOR)

    Time: From the time of documentation of tumor response to the first recorded occurrence of disease progression (PD) or death from any cause (whichever occurs first), through end of study (up to 4 years)

    Description: DCR is defined as the percentage of participants who achieve stable disease (SD) or better (determined by the investigator according to RECIST v1.1 criteria for solid tumors or Lugano classification for lymphoma) greater than (>) 6 weeks during the study in the response-evaluable population.

    Measure: Phase 2: Disease Control Rate (DCR)

    Time: From the first dose until best response is achieved (up to 4 years)

    Description: TTR is defined as the time from the date of first study drug administration to the date of first documented PR or better by the investigator for responders according to RECIST v1.1 for participants with solid tumors or Lugano classification for lymphoma.

    Measure: Phase 2: Time to Response (TTR)

    Time: From the date of first study drug administration to the date of first documented PR or better (up to 4 years)

    Description: TTP is defined as the time from the date of the first dose administration to the date of first documented progressive disease and will be determined by the investigator according to RECIST v1.1 for participants with solid tumors or Lugano classification for lymphoma.

    Measure: Phase 2: Time to Progression (TTP)

    Time: From the date of first study drug administration to the date of first documented PD (up to 4 years)

    Description: PFS is defined as the time from the date of the first dose administration to the date of first documentation of progressive disease or death due to any cause, whichever occurs first and will be determined by the investigator according to RECIST v1.1 for participants with solid tumors or Lugano classification for lymphoma.

    Measure: Phase 2: Progression-free Survival (PFS)

    Time: From the date of the first dose administration to the date of first documentation of PD or death due to any cause whichever occurs first, through the end of the study (up to 4 years)

    Description: OS is defined as the time from the date of the first dose administration to the date of death.

    Measure: Phase 2: Overall Survival (OS)

    Time: From the date of first study drug administration to the date of death (up to 4 years)

    Measure: Phase 2: Number of Participants With TAK-981-Small Ubiquitin-like Modifier (TAK-981-SUMO) Adduct Formation and SUMO Pathway Inhibition in Skin/Blood

    Time: Up to 48 months

    Measure: COVID-19 Expansion: Number of Participants Reporting one or More TEAEs

    Time: Up to 9 months

    Description: Severity Grades will be evaluated as per National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE), version 5.0.

    Measure: COVID-19 Expansion: Number of Participants Based on Severity of TEAEs

    Time: Up to 9 months

    Measure: COVID-19 Expansion: Duration of TEAEs

    Time: Up to 9 months

    Description: NEWS determines the degree of illness of participants and prompts critical care intervention. It will be based on the score allocated to respiratory rate, peripheral capillary oxygen saturation, any supplemental oxygen, temperature, systolic blood pressure, heart rate and level of consciousness.

    Measure: COVID-19 Expansion: Change from Baseline in National Early Warning Score (NEWS)

    Time: Up to 9 months

    Description: Percentage of participants will be reported based on severity rating on a 6-point ordinal scale, which will include: 1 (death); 2 (hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation, hospitalized); 3 (on non-invasive ventilation or high flow oxygen devices); 4 (hospitalized, requiring supplemental oxygen); 5 (hospitalized, not requiring supplemental oxygen); and 6 (not hospitalized).

    Measure: COVID-19 Expansion: Percentage of Participants Reporting Each Hospitalization Severity Rating

    Time: Up to 9 months

    Description: Change from Baseline in SARS-CoV-2 viral Load in nasopharyngeal or oropharyngeal samples will be determined by viral response. The nasopharyngeal swab will be collected from both nostrils or from the same nostril every time.

    Measure: COVID-19 Expansion: Change From Baseline in SARS-CoV-2 Viral Load in Nasopharyngeal or Oropharyngeal Samples

    Time: Up to 9 months

    Measure: COVID-19 Expansion: Percentage of Participants Requiring Oxygen Supplementation; Assisted or Positive Pressure Non-invasive Ventilation; and Invasive Ventilation, on Days 3, 5, 8, 11, 15, and 30

    Time: Days 3, 5, 8, 11, 15, and 30

    Measure: COVID-19 Expansion: Percentage of Participants That met Intensive Care Unit (ICU) Criteria

    Time: Up to 9 months

    Measure: COVID-19 Expansion: Duration of Hospitalization

    Time: Up to 9 months

    Description: Time from the first dose of TAK-981 to viral load negativity (below level of detection).

    Measure: COVID-19 Expansion: Time to Viral Ribonucleic Acid (RNA) Negativity in Nasopharyngeal or Oropharyngeal Samples

    Time: Up to 9 months

    Description: Time from first dose of TAK-981 to participant's discharge or to NEWS score <=3. NEWS determines the degree of illness of participants and prompts critical care intervention. It will be based on the score allocated to respiratory rate, peripheral capillary oxygen saturation, any supplemental oxygen, temperature, systolic blood pressure, heart rate and level of consciousness.

    Measure: COVID-19 Expansion: Time to Discharge or to a NEWS of Less Than or Equal to (<=) 3 and Maintained for 24 Hours

    Time: Up to 9 months

    Measure: COVID-19 Expansion: Number of Deaths in Hospital due to any Cause in First 30 Days and in 90 Days

    Time: Days 30 and 90
    2 The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19, a Prospective Cohort Study

    A novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) emerged at December 2019 in Wuhan, China, and soon caused a large global outbreak. The delayed treatment for many chronic diseases, due to the concern of SARS-CoV-2 infection, is an increasing serious problem. Here the investigators investigate the safety of chemotherapy for patients with gynecological malignancy in Wuhan, the center of high-risk regions of COVID-19.

    NCT04341480
    Conditions
    1. Gynecological Cancer
    Interventions
    1. Drug: Chemotherapy
    MeSH:Neoplasms
    HPO:Neoplasm

    Primary Outcomes

    Description: Incidence rate of SARS-CoV-2 infection within the whole period of the study.

    Measure: SARS-CoV-2 infection

    Time: through study completion, an average of 3 months.

    Secondary Outcomes

    Description: Tumor response by determining changes (PD, SD, PR, CR) according to Response Evaluation Criteria in Solid Tumours (RECIST), version 1.1

    Measure: Tumor response

    Time: 6 weeks after enrollment.

    Description: Safety and tolerability of chemotherapy as measured by the Common Terminology Criteria for Adverse Events (version 4.0)

    Measure: Safety and tolerability of chemotherapy as measured by the Common Terminology

    Time: through study completion, an average of 3 months.

    Description: To evaluate quality of life (QOL) for the subjects undergoing this treatment, using validated tools. QOL will be assessed every 3 months during treatment course. [Functional Assessment of Cancer Therapy - Ovarian Cancer questionnaire (score range from 0 to 160. Higher scores represent better quality of life. questionnaire core-30 (QLQ-C30).

    Measure: Quality of Life (QOL) measures using Functional Assessment of Cancer Therapy (FACT- ovarian cancer)

    Time: through study completion, an average of 3 months.
    3 Impact of the COVID-19 Pandemic on Changes in Therapeutic Strategies in Gynecological Oncology

    The current infection with the Coronavirus SARS-CoV-2 (COVID-19) is an exceptional health situation which requires an adaptation of our management practices in gynecological oncology. Data from the literature suggest that infection with Coronavirus is serious in subjects with cancer with a risk of severe form 5 times higher than that of the population without cancer and a risk of death multiplied by 8. In addition, the risk of infection would be 3 times greater in case of cancer. Faced with the COVID-19 epidemic, the investigator must organize themselves to ensure continuity in the treatment of patients with gynecological cancer but also adapt our practices in the management (CPR, teleconsultation, adaptation of treatment or even postponement of treatment). The objective of the High Council of Public Health is to be able to ensure adequate oncological care avoiding any potential loss of chance concerning the care of cancer: people affected must, despite the pandemic, have care allowing the same level of curability (localized cancers) or the same life expectancy (advanced cancers). This must be done by limiting as much as possible the impact on the organization of the service, the organization of patient follow-up and the psychological impact that these possible modifications could have. The hypotheses of our study are that the exceptional health situation linked to this pandemic leads to a change in the care of patients with gynecological cancer associated with a psychological impact and increased anxiety of patients during their care. Despite the extent of the pandemic, very little existing data makes it possible to define recommendations with a sufficient level of evidence.

    NCT04351139
    Conditions
    1. Gynecologic Cancer
    2. Breast Neoplasm Female
    3. Uterine Neoplasms
    4. Ovarian Neoplasms
    5. Uterine Cervical Neoplasms
    6. Vulvar Neoplasms
    7. Vaginal Neoplasms
    Interventions
    1. Other: modification of the planned therapeutic management
    MeSH:Neoplasms Breast Neoplasms Ovarian Neoplasms Uterine Cervical Neoplasms Uterine Neoplasms Vulvar Neoplasms Vaginal Neoplasms
    HPO:Breast carcinoma Cervical polyp Cervix cancer Neoplasm Neoplasm of the breast Ovarian neoplasm Uterine neoplasm Vaginal neoplasm Vulvar neoplasm

    Primary Outcomes

    Description: modification of the planned therapeutic management

    Measure: percentage of patients with a change in the planned therapeutic management (surgery, chemotherapy, radiotherapy, hormone therapy)

    Time: Day O
    4 SARS-CoV-2 Infection in Patients With Hematological Malignancies: the Italian Hematology Alliance

    This is a retrospective/prospective, cohort, non-interventional observational study. This means that all patients with documented COVID and HM diagnosed between February 2020 and study initiation will compose the retrospective part, while those diagnosed after study approval will enter prospective part. The total duration of the study will be 12 months. The study population will must be older than 18 years of age with HM and SARS-CoV-2 infection. All patients with documented SARS-CoV-2 infection (COVID) and history or active hematological malignancies, who refer to any Hematological Unit will be included.

    NCT04352556
    Conditions
    1. SARS-CoV-2 Infection
    2. Hematological Malignancies
    MeSH:Infection Neoplasms Hematologic Neoplasms
    HPO:Hematological neoplasm Leukemia Neoplasm

    Primary Outcomes

    Description: The percentage of HM patients with COVID-19 who died.

    Measure: To evaluate mortality.

    Time: At 2 months from study initiation

    Description: We will assess the correlation between some biochemical parameters at diagnosis of COVID (i.e. hemoglobin, platelets, lymphocytes, clotting tests, CRP), each on the basis of its specific unit of measure, and mortality.

    Measure: To evaluate potential predictive biochemical parameters of mortality.

    Time: At 2 months from study initiation

    Description: We will assess the correlation between HM-related parameters at diagnosis of COVID [i.e. disease type (leukemia, lymphomas, myeloma), disease status (remission / stable / progression), therapy status (on / off therapy)] and mortality.

    Measure: To evaluate potential predictive HM-related parameters of mortality.

    Time: At 2 months from study initiation

    Description: We will assess the correlation between COVID severity [mild (non-pneumonia and mild pneumonia), severe (dyspnea, respiratory frequency ≥ 30/min, SpO2 ≤ 93%, PaO2/FiO2 < 300 and/or lung infiltrates > 50%) and critical (respiratory failure, septic shock, and/or multiple organ disfunction or failure)] and mortality

    Measure: To evaluate COVID severity as predictive parameter of mortality.

    Time: At 2 months from study initiation

    Secondary Outcomes

    Description: Description of the different types of hematological malignancies (WHO criteria) in patients with SARS-CoV-2 infection. All aggregated data will be stratified on the basis of COVID severity: mild (non-pneumonia and mild pneumonia), severe (dyspnea, respiratory frequency ≥ 30/min, SpO2 ≤ 93%, PaO2/FiO2 < 300 and/or lung infiltrates > 50%) and critical disease (respiratory failure, septic shock, and/or multiple organ disfunction or failure)

    Measure: Epidemiology of patients with HM infected by SARS-CoV-2with any spectrum of illness severity

    Time: At 6 months from study initiation

    Description: Characterization of clinical and biochemical profile of patients with SARS-CoV-2 positivity.

    Measure: Definition of complete clinical picture of COVID-19 in HM

    Time: At 2 months from study initiation

    Description: Assessment of HM status post SARS-CoV-2 infection stratified as no implication, loss of response, progression of the hematological disease.

    Measure: Evolution of HM

    Time: At 2 months from study initiation

    Description: Percentage of HM patients being admitted to ICU requiring mechanical ventilation, or death stratified per disease type, status, per off-therapy/on-therapy, per type of therapy (chemo, immunotherapy, cell therapy, stem cell transplant).

    Measure: To evaluate admission to ICU requiring mechanical ventilation or death per characteristics

    Time: At 2 months from study initiation

    Measure: Viral dynamics in infected HM patients

    Time: At 12 months from study initiation
    5 The COVID-19 and Cancer Consortium (CCC19) Registry

    In this study we will collect granular information on cancer patients infected with COVID-19, as rapidly as possible. The mechanism for collection of this information is a de-identified centralized registry housed at Vanderbilt University Medical Center, with data donations from internal and external health care professionals.

    NCT04354701
    Conditions
    1. COVID-19
    2. Invasive Malignancy (Any Type)
    Interventions
    1. Other: Web-based REDCap survey
    MeSH:Neoplasms
    HPO:Neoplasm

    Primary Outcomes

    Description: The survey includes five parts: 1) basic demographics about the patient, including performance status and comorbidities; 2) initial COVID-19 diagnosis and clinical course; 3) cancer and cancer treatment details; 4) respondent details; 5) long-term COVID-19 outcomes.

    Measure: Web-based REDCap survey

    Time: Approximately 18 months
    6 Tociluzumab for Cytokine Release Syndrome With SARS-CoV-2: An Open-Labeled, Randomized Phase 3 Trial

    This phase III trial compares the effect of adding tocilizumab to standard of care versus standard of care alone in treating cytokine release syndrome (CRS) in patients with SARS-CoV-2 infection. CRS is a potentially serious disorder caused by the release of an excessive amount of substance that is made by cells of the immune system (cytokines) as a response to viral infection. Tocilizumab is used to decrease the body's immune response. Adding tocilizumab to standard of care may work better in treating CRS in patients with SARS-CoV-2 infection compared to standard of care alone.

    NCT04361552
    Conditions
    1. Cerebrovascular Accident
    2. Chronic Obstructive Pulmonary Disease
    3. Chronic Renal Failure
    4. Coronary Artery Disease
    5. Diabetes Mellitus
    6. Malignant Neoplasm
    7. SARS Coronavirus 2 Infection
    Interventions
    1. Other: Best Practice
    2. Biological: Tocilizumab
    MeSH:Infection Neoplasms Lung Diseases, Obstructive Pulmonary Disease, Chronic Obstructive Stroke Kidney Failure, Chronic Coronary Artery Disease
    HPO:Chronic pulmonary obstruction Coronary artery atherosclerosis Neoplasm Pulmonary obstruction Stroke

    Primary Outcomes

    Description: The 7-day length of invasive MV for each arm will be estimated with 95% confidence intervals (CIs) using the exact binomial distribution. Their difference by the arms will be tested by Cochran-Mantel-Haenszel (CMH) test stratified by the age group and Sequential Organ Failure Assessment (SOFA) score at significance level of 0.05.

    Measure: 7-day length of invasive mechanical ventilation (MV)

    Time: Up to 7 days

    Description: Defined as death within 30-day after randomization. The 30-day mortality rate for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

    Measure: 30-day mortality rate

    Time: Up to 30-day after randomization

    Secondary Outcomes

    Description: The rate of ICU transfer for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

    Measure: Rate of intensive care (ICU) transfer

    Time: Up to 2 years

    Description: The rate of invasive mechanical ventilation for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

    Measure: Rate of invasive mechanical ventilation

    Time: Up to 2 years

    Description: The rate of tracheostomy for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

    Measure: Rate of tracheostomy

    Time: Up to 2 years

    Description: Will first be described by median and inter-quartile, and then compared between two arms by Wilcoxon Sum-Rank test

    Measure: Length of ICU stay

    Time: Up to 2 years

    Measure: Length of hospital stay

    Time: Up 2 years
    7 COVID-19 Serodiagnosis in Oncology

    EVIDENCE is a non interventional, French, multicenter study. Patients will be screened by local severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoassay in their oncology department (rapid diagnostic test (RDT) or enzyme-linked immunosorbent assay (ELISA)). In patients with positive local SARS-CoV-2 immunoassay, a centralized SARS-CoV-2 ELISA will be performed in order to double check the immune response of all patients considered immune by local immunoassay.

    NCT04367870
    Conditions
    1. Oncology
    MeSH:Neoplasms
    HPO:Neoplasm

    Primary Outcomes

    Description: The primary endpoint of this study is the recurrence of COVID-19 within 3 months following the immunoassay-positive result obtained before the inclusion in the study. The recurrence is defined by the presence of symptoms confirmed either by a positive reverse transcription-polymerase chain reaction (RT-PCR) result for SARS-CoV-2 or by the adjudication committee. Immunoassay will be said positive as per the predefined reference corresponding to the immunoassay.

    Measure: To evaluate the ability of SARS-CoV-2 immunoassays, following a positive result, to identify patients with very low risk of recurrence of COVID-19 within 3 months.

    Time: 3 months

    Secondary Outcomes

    Description: The prevalence is the ratio between the number of immunoassay-positive patients and the number of patients tested over a predefined period, i.e the whole duration of the study and by 1-month intervals.

    Measure: To estimate the prevalence of patients immunized to the SARS-CoV-2 virus in an oncology population over the whole study duration and within one-month periods.

    Time: 6 months

    Description: Agreement between the different immunoassays and the centralized ELISA, using the centralized ELISA as benchmark.

    Measure: To estimate the discordance rate between local immunoassay and a centralized ELISA in patients with a positive immunoassay, whatever the immunoassay.

    Time: 6 months

    Description: COVID-19 recurrence within 6 months following an immunoassay-positive result.

    Measure: To identify patients with very low risk of recurrence of COVID-19 within 6 months following a positive immunoassay result.

    Time: 6 months

    Description: Quantitative and qualitative detection of SARS-CoV-2-related antibodies and immune serum markers at baseline, 2-3 months and 4-6 months post-inclusion, in a subgroup of 200 patients.

    Measure: To characterize the evolution over time of the serologic response against SARS-CoV-2 (in a subgroup of patients).

    Time: 6 months
    8 Tocilizumab in Hospitalized Cancer Patients With Coronavirus 2019 (SARS-CoV-2) and Severe Complications of Coronavirus Disease 19 (COVID-19)

    This phase II expanded access trial will study how well tocilizumab works in reducing the serious symptoms including pneumonitis (severe acute respiratory distress) in patients with cancer and COVID-19. COVID-19 is caused by the SARS-CoV-2 virus. COVID-19 can be associated with an inflammatory response by the immune system which may also cause symptoms of COVID-19 to worsen. This inflammation may be called "cytokine storm," which can cause widespread problems in the body. Tocilizumab is a medicine designed to block the action of a protein called interleukin-6 (IL-6) that is involved with the immune system and is known to be a key factor for problems with excessive inflammation. Tocilizumab is effective in treating "cytokine storm" from a type of cancer immunotherapy and may be effective in reducing the inflammatory response and "cytokine storm" seen in severe COVID-19 disease. Treating the inflammation may help to reduce symptoms, improve the ability to breathe without a breathing machine (ventilator), and prevent patients from having more complications.

    NCT04370834
    Conditions
    1. Hematopoietic and Lymphoid Cell Neoplasm
    2. Malignant Solid Neoplasm
    3. Pneumonia
    4. Pneumonitis
    5. Severe Acute Respiratory Distress Syndrome
    6. Symptomatic COVID-19 Infection Laboratory-Confirmed
    Interventions
    1. Biological: Tocilizumab
    MeSH:Laboratory Infection Neoplasms Pneumonia Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury
    HPO:Neoplasm Pneumonia

    Primary Outcomes

    Measure: Clinical outcome as evaluated by the 7-category Clinical Status Ordinal Scale

    Time: At least 60 days, up to 1 year
    9 Phase 1/2A Study of Rintatolimod and IFN-Alpha Regimen in Cancer Patients With Mild or Moderate COVID-19 Infection

    This prospective phase I/IIa trial studies the side effects of rintatolimod and Intron A (IFNa) alpha-2b in treating cancer patients with mild or moderate COVID-19 infection. Interferon alpha is a protein important for defense against viruses. It activates immune responses that help to clear viral infection. Rintatolimod is double stranded ribonucleic acid (RNA) designed to mimic viral infection by stimulating immune pathways that are normally activated during viral infection. Giving rintatolimod and interferon alpha-2b may activate the immune system to limit the replication and spread of the virus.

    NCT04379518
    Conditions
    1. Malignant Neoplasm
    2. SARS Coronavirus 2 Infection
    Interventions
    1. Biological: Recombinant Interferon Alfa-2b
    2. Drug: Rintatolimod
    MeSH:Infection Communicable Diseases Neoplasms
    HPO:Neoplasm

    Primary Outcomes

    Description: This refers to the frequency of grade 3 or 4 AEs considered to be possibly, probably or definitely related to the treatment regimen. Toxicity will be assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE version [v] 5.0).

    Measure: Incidence of adverse events (AEs)

    Time: Up to 30 days post treatment intiation

    Description: will be evaluated based on quantitative polymerase chain reaction PCR

    Measure: Kinetics of viral load in nasopharyngeal swabs

    Time: Up to 30 days post treatment initiation

    Secondary Outcomes

    Description: Will be analyzed using quantitative polymerase chain reaction (PCR).

    Measure: Kinetics of viral load in the peripheral blood and nasopharyngeal swabs

    Time: During the course of treatment up to day 30

    Description: The circulatory inflammatory mediators include C-reactive protein (CRP), cytokines, chemokines, interferons.

    Measure: Kinetics of changes of the immune subsets and circulating inflammatory mediators in peripheral blood

    Time: During the course of treatment up to day 30

    Description: The binary endpoint of 30-day mortality will be analyzed using a logistic regression model.

    Measure: 30-day mortality

    Time: At 30 days post treatment initiation

    Description: Rate of hospitalization due to infection

    Measure: Hospitalization due to infection

    Time: Up to 30 days post treatment initiation

    Description: Will be tested in nasopharyngeal swabs and blood cells of patients

    Measure: Determine known mediators of antiviral immunity

    Time: UP to 30 days post treatment initiation

    Other Outcomes

    Description: ARDS will be defined by Berlin criteria

    Measure: acute respiratory distress syndrome (ARDS)

    Time: Up to 30 days post treatment initiation

    Description: Need for mechanical ventilation

    Measure: respiratory failure requiring mechanical ventilation

    Time: up to 30 days post treatment initiation
    10 Myeloproliferative Neoplasms (MPN) and COVID-19

    An increased risk of both venous and arterial thromboembolism was noted in reports from SARS-CoV-2-infected patients in China and has been confirmed in autopsy findings from patients who experienced sudden death. Myeloproliferative Neoplasms (MPNs), which encompass polycythemia vera, essential thrombocythemia and primary myelofibrosis, are thrombophilic disorders with a natural propensity to thrombosis that is fuelled by the intrinsic activation of inflammatory cytokines. It therefore follows that an underlying diagnosis of MPN may increase the risk of worse clinical outcomes and death during periods of active Covid-19 disease. This ambispective, observational study aims to elucidate the key factors which affect the clinical course of patients with MPN who develop Covid-19 disease.

    NCT04385160
    Conditions
    1. Myeloproliferative Neoplasm
    2. COVID
    MeSH:Neoplasms Myeloproliferative Disorders
    HPO:Myeloproliferative disorder Neoplasm

    Primary Outcomes

    Description: Incidence of cases of MPN patients with COVID-19 experiencing pulmonary embolism

    Measure: pulmonary embolism (PE)

    Time: 2 and a half months

    Secondary Outcomes

    Description: Incidence of cases reporting at least one fatal or non fatal thrombotic event reported in therapy of MPN

    Measure: fatal or non fatal thrombotic event

    Time: 2 and a half months

    Description: Incidence of cases reporting at least one COVID-19 worsening outcome as Continuous Positive Airway Pressure (CPAP)

    Measure: Continuous Positive Airway Pressure (CPAP)

    Time: 2 and a half months

    Description: Incidence of cases reporting at least one COVID-19 worsening outcome as invasive ventilation

    Measure: invasive ventilation

    Time: 2 and a half months

    Description: Incidence of cases reporting at least one COVID-19 worsening outcome as Intensive Care Unit (ICU)

    Measure: admission in Intensive Care Unit (ICU)

    Time: 2 and a half months

    Description: incidence of death

    Measure: death

    Time: 2 and a half months

    Description: Type of treatments and interventions applied for MPN during COVID-19 and any change reported in therapy of MPN

    Measure: treatments and interventions applied for MPN

    Time: 2 and a half months

    Description: Type of treatments and interventions applied for COVID-19

    Measure: treatments and interventions applied for COVID-19

    Time: 2 and a half months

    Description: Odds Ratios (ORs) of the outcome and 95% Confidence Intervals (CIs) associated with patients' characteristics and treatments

    Measure: thrombotic events association to patients characteristic and treatments

    Time: 2 and a half months
    11 NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study

    This study collects blood samples, medical information, and medical images from patients who are being treated for cancer and have a positive test for SARS CoV-2, the new coronavirus that causes the disease called COVID-19. Collecting blood samples, medical information, and medical images may help researchers determine how COVID-19 affects the outcomes of patients undergoing cancer treatment and how having cancer affects COVID-19.

    NCT04387656
    Conditions
    1. COVID-19 Infection
    2. Hematopoietic and Lymphoid Cell Neoplasm
    3. Malignant Solid Neoplasm
    4. Metastatic Malignant Solid Neoplasm
    Interventions
    1. Procedure: Biospecimen Collection
    2. Other: Data Collection
    3. Other: Quality-of-Life Assessment
    4. Other: Questionnaire Administration
    MeSH:Neoplasms
    HPO:Neoplasm

    Primary Outcomes

    Description: Distinguish the likelihood of severe COVID19 (for example, requiring hospitalization, requiring intensive care unit [ICU] treatment or requiring a ventilator) and death due to COVID-19 for patients with versus without the factor. Among subgroups of at least 50 patients, evaluate using chi-square tests as well as death and hospitalization rates.

    Measure: Patient variables (factors) associated with severe acute respiratory syndrome (SARS) coronavirus 2 (COVID-19) severity

    Time: Up to 2 years

    Description: Describe the degree to which COVID-19 interrupts, delays, or otherwise alters cancer treatment for pediatric patients and subgroups of adult patients defined by cancer type and/or treatment modality. Describe the association between changes in cancer therapy and clinical outcomes. Evaluate association of COVID-19 with outcome by comparison to historical controls in subgroups of at least 50 patients using log rank tests to assess time to survival event.

    Measure: Effects of COVID-19 on cancer therapy and association with clinical outcomes

    Time: Up to 2 years

    Description: Will be measured using items from the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 Profile.

    Measure: Physical health (patient-reported health-related quality of life)

    Time: Up to 2 years

    Other Outcomes

    Description: Analysis will include time to development of antibodies, prevalence of cytokine abnormalities, and genome-wide association study (GWAS) to define genetic polymorphisms associated with severe COVID-19 disease/mortality.

    Measure: Collection of blood specimens for future biomarker studies

    Time: Up to 2 years
    12 Randomised, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies

    The primary objective of this phase 2, multicentric, placebo-controlled double-blind, randomized study is to evaluate the efficacy of the combination of hydroxychloroquine and azithromycine on the viral load drop at day 5 among patients with COVID-19 and hematological malignancies.

    NCT04392128
    Conditions
    1. COVID19
    2. Hematologic Malignancy
    Interventions
    1. Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil]
    2. Drug: Azithromycin 250 MG Oral Capsule
    3. Drug: Placebo oral tablet
    4. Drug: Placebo oral capsule
    MeSH:Neoplasms Hematologic Neoplasms
    HPO:Hematological neoplasm Leukemia Neoplasm

    Primary Outcomes

    Description: Locally evaluated rate of viral response. Favorable response is defined as (1) complete response : negative PCR (absence of detectable signal with a minimum of 40 cycles) or (2) major response : detectable signal but with an increased number of cycles > or egal to 10 compared to initial PCR. Response failure is defined as (1) minor response : detectable signal but with an increased number of cycles < 10 compared to initial PCR or (2) stabilisation or worsening of the viral load.

    Measure: Evaluation of the efficacy of hydroxychloroquine and azithromyncine on the viral load drop at day 5.

    Time: 5 days of treatment

    Secondary Outcomes

    Description: Duration of fever - duration of respiratory symptoms (cough, dyspnea) - duration of other COVID-19 related symptoms (digestive symptoms, ageusia, anosmia)

    Measure: Clinical evolution

    Time: up to 3 months

    Description: Less or equal to 94% oxygen saturation - need to initiate oxygenotherapy - occurrence of respiratory distress - patient transfer in intensive care unit - need of mechanical ventilation - occurrence of non-respiratory organ failure - occurrence of septic shock

    Measure: Proportion of patients progressing to a severe form

    Time: up to 3 months

    Description: Date and cause of death

    Measure: Mortality

    Time: up to 1 and 3 months

    Description: SARS-CoV-2 viral load by PCR on nasopharyngeal swab at day 10 (if positive at day 5) : rate of negativation and comparison of number of cycles with previous samples

    Measure: Evaluation of viral load drop

    Time: at day 10

    Description: Frequence and causality of all-grade cardiac adverse events - frequence and causality of grade > 1 adverse events for other adverse events - frequence and causality of serious adverse events (CTCAE v5)

    Measure: Tolerance of study treatment

    Time: up to 3 months

    Description: Collection of serum to realize serological tests

    Measure: Evaluation of the seroconversion

    Time: at inclusion, day 10, day 30 and day 90 after treatment

    Description: Phenotypic and functional study of NK lymphocytes at inclusion, Retrospective analysis on frozen cells.

    Measure: NK immunological study

    Time: at day 10 and day 30 after treatment

    Description: Duration of hospitalisation (conventional, intensive care, reanimation)

    Measure: Hospitalisation duration

    Time: up to 3 months

    Description: Patient follow-up during 3 months : hematological status and associated therapy

    Measure: Impact of the study treatment on the treatment of the hematological disease

    Time: up to 3 months

    Description: ECG (using connected machine to allow monitoring at home)

    Measure: Monitoring of the QT space

    Time: at inclusion, day 2, day 5, day 10

    Description: Dosage of residual concentration of azithromycine and hydroxychloroquine.

    Measure: Dosage of residual concentration of azithromycine and hydroxychloroquine.

    Time: at day 5 and day 10

    Description: Phenotypic and functional study of T lymphocytes at inclusion, Retrospective analysis on frozen cells.

    Measure: T immunological study

    Time: at day 10 and day 30 after treatment
    13 An Observational Study to Identify the Issues and Challenges in Cancer Patients on Active Treatment During the COVID-19 Pandemic and the Resulting Lockdown

    In view of increasing cases of SARS-CoV-2 leading to the COVID-19 Pandemic in India,there has been unprecedented restrictions on travel, work and other aspects of daily life. Our study has been designed to collect data of cancer patients to analyze their issues and challenges during Covid-19 Pandemic.

    NCT04406844
    Conditions
    1. Oncology Patients
    MeSH:Neoplasms
    HPO:Neoplasm

    Primary Outcomes

    Description: To focus on basic issues encountered by oncology patients such as transportation, medical facility, healthcare support, disease apprehension etc

    Measure: Oncology patients

    Time: 4-8 weeks
    14 Oncological Surgery in Times of COVID-19: Effectiveness of Preoperative Screening for Sars-Cov-2

    To evaluate the incidence of patients with a positive test for SARS-CoV-2, performed in the preoperative screening for patients treated at the institution

    NCT04434261
    Conditions
    1. SARS-CoV-2
    2. Oncology
    3. Surgery
    Interventions
    1. Diagnostic Test: PT-PCR test for SARS-CoV-2
    MeSH:Neoplasms
    HPO:Neoplasm

    Primary Outcomes

    Description: Describe the incidence of patients with a positive test for SARS-CoV-2, detected in the preoperative screening program in our center

    Measure: Incidence of patients with a positive test for SARS-CoV-2, detected in the preoperative screening program

    Time: May- December 2020

    Secondary Outcomes

    Description: Describe the incidence of SARS-CoV-2 infection in the postoperative period in patients with negative screening test.

    Measure: Incidence of SARS-CoV-2 infection in the postoperative period in patients with negative screening test;

    Time: Up to 30 days

    Description: Postoperative complications will be recorded, according to the Clavien-Dindo classification.

    Measure: Postoperative complications

    Time: Up to 30 days

    Description: To evaluate the risk of all-cause mortality

    Measure: Mortality

    Time: 30 days

    Description: Assess the impact of delayed cancer treatment

    Measure: Delay in the cancer treatment

    Time: May 2020- March 2021
    15 Longitudinal Prospective Cohort Study to Describe the Clinical Characteristics of COVID-19, the Acquired Immune Response and the Biological and Clinical Parameters of Patients Followed in Oncology by the Saint-Joseph Hospital Group, Paris, France for a Period of 6 Months During the COVID-19 Pandemic in 2020

    This registry will allow to evaluate the correlation of the incidence and evolution of associated symptoms of infection of COVID-19 with the biological and clinical parameters in patients followed in Oncology during the COVID-19 pandemic.

    NCT04437719
    Conditions
    1. Oncology
    2. COVID-19
    Interventions
    1. Other: Obvio-19 app
    MeSH:Neoplasms
    HPO:Neoplasm

    Primary Outcomes

    Description: Evaluation of the proportion of patients with COVID-19 infection's symptoms known to be associated with COVID-19 diagnosis (fever, cough, loss of taste and smell, sore throat, muscle pain, diarrhea, fatigue, difficulty eating and drinking and shortness of breath) followed during a period of 6 months.

    Measure: COVID-19 infection's symptoms

    Time: Observational period of 6 months

    Secondary Outcomes

    Description: To assess the prevalence and course of symptoms of COVID-19 infection of patients followed during a period of 6 months.

    Measure: Incidence and course of symptoms of COVID-19 infection

    Time: During a period of 6 months

    Description: To establish the correlation of the COVID-19 infection with the biological and clinical data of patients from the Oncology cohort of the Groupe hospitalier Paris Saint-Joseph in Paris followed during a period of 6 months.

    Measure: Correlation of the COVID-19 infection with the biological and clinical data of patients

    Time: After a period of 6 months
    16 Randomized Double-Blind Phase 2 Trial of Ibrutinib Versus Standard Treatment for COVID-19 Illness Requiring Hospitalization With Safety Lead-In

    This phase Ib/II trial studies the side effects and best dose of ibrutinib and how well it works in treating patients with COVID-19 requiring hospitalization. Ibrutinib may help improve COVID-19 symptoms by lessening the inflammatory response in the lungs, while preserving overall immune function. This may reduce the need to be on a ventilator to help with breathing.

    NCT04439006
    Conditions
    1. Aplastic Anemia
    2. Hematopoietic and Lymphoid Cell Neoplasm
    3. Malignant Solid Neoplasm
    4. Monoclona
    5. Monoclonal B-Cell Lymphocytosis
    6. Monoclonal Gammopathy of Undetermined Significance
    7. Myelodysplastic Syndrome
    8. Symptomatic COVID-19 Infection Laboratory-Confirmed
    Interventions
    1. Other: Best Practice
    2. Drug: Ibrutinib
    MeSH:Laboratory Infection Neoplasms Myelodysplastic Syndromes Anemia, Aplastic Paraproteinemias Monoclonal Gammopathy of Undetermined Significance Lymphocytosis
    HPO:Aplastic anemia Erythroid hypoplasia Hypoplastic anemia Lymphocytosis Myelodysplasia Neoplasm

    Primary Outcomes

    Description: Associations between baseline characteristics and the primary endpoint will be evaluated with logistic regression, adjusting for arm. These analyses will be largely descriptive, as a result of a limited sample size.

    Measure: Proportion of patients with diminished respiratory failure and death

    Time: During hospitalization for COVID-19 infection or within 30 days of registration

    Measure: Death

    Time: During hospitalization for COVID-19 infection or within 30 days of registration

    Secondary Outcomes

    Description: Fever-free will be assessed by a temperature of < 100.5 degrees Fahrenheit orally. Will be estimated for each arm using the method of Kaplan-Meier. Medians estimates and/or estimates at specific time points will be provided with 95% confidence intervals.

    Measure: Time from study initiation to 48 hours fever-free

    Time: Up to 14 days

    Description: Will be estimated for each arm using the method of Kaplan-Meier. Medians estimates and/or estimates at specific time points will be provided with 95% confidence intervals.

    Measure: Duration of hospitalization

    Time: Up to 14 days

    Measure: Time in intensive care unit (ICU)

    Time: Up to 14 days

    Measure: Time to ICU admission

    Time: Up to 14 days

    Measure: Number of days requiring supplemental oxygen

    Time: Up to 14 days

    Measure: Total days of mechanical ventilation

    Time: Up to 14 days

    Measure: Time to mechanical ventilation

    Time: Up to 14 days

    Measure: Shock and need for pressure support

    Time: Up to 14 days

    Measure: Incidence of any infection (viral, fungal, bacterial)

    Time: Up to 14 days

    Measure: Time to clinical resolution

    Time: Up to 14 days

    Description: Adverse events will be summarized by grade, type, and attribution (regardless of attribution and treatment-related) for each arm.

    Measure: Incidence of grade 3 or higher adverse events

    Time: Up to 12 months

    Description: The proportion of patients with viral clearance at the time of hospital discharge will be estimated with 95% confidence intervals for each arm.

    Measure: At the end of therapy (day 14)

    Time: Up to 14 days

    Description: Will be estimated for each arm using the method of Kaplan-Meier. Medians estimates and/or estimates at specific time points will be provided with 95% confidence intervals.

    Measure: Time to viral clearance

    Time: Up to 12 months

    Description: Patients will be followed for up to 12 months or until death or withdrawal of study consent for further follow-up. Following hospitalization, study visits will be telephone or video encounters.

    Measure: Survival

    Time: Up to12 months
    17 A Double-Blind, Randomized, Placebo-Controlled Phase II Study of Lopinavir/Ritonavir Versus Placebo in COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year

    This phase II trial studies how well lopinavir/ritonavir works in treating COVID-19 positive patients with cancer and a weakened immune system (immune-suppression) in the last year and have mild or moderate symptoms caused by COVID-19. Lopinavir/ritonavir may help to lessen or prevent COVID-19 symptoms from getting worse in cancer patients.

    NCT04455958
    Conditions
    1. Hematopoietic and Lymphoid Cell Neoplasm
    2. Malignant Solid Neoplasm
    3. Symptomatic COVID-19 Infection Laboratory-Confirmed
    Interventions
    1. Drug: Lopinavir/Ritonavir
    2. Drug: Placebo Administration
    3. Other: Questionnaire Administration
    MeSH:Laboratory Infection Neoplasms
    HPO:Neoplasm

    Primary Outcomes

    Description: Will be compared to the time of randomization. The severity of symptoms will be categorized as mild, moderate, severe, or critical according to the grading of symptoms. The proportion of participants with progression to more severe symptoms between treatments groups will be compared using a Fisher's Exact test at a 0.05 significance level.

    Measure: Severity of symptoms

    Time: 3 months

    Secondary Outcomes

    Description: Will be defined as improvement on symptoms: yes or no. Will be compared between treatment groups using log-rank test. A 95% confidence interval of treatment rate difference in symptom progression will be calculated by the Wald method.

    Measure: Clinical benefit rate of lopinavir/ritonavir

    Time: 3 months

    Description: Will be compared between treatment groups using log-rank test.

    Measure: Time to symptom progression

    Time: From randomization to the first documented symptoms progression, assessed up to 3 months

    Description: Will be compared between treatment groups using log-rank test.

    Measure: Time to improvement of participants

    Time: From randomization to first documented complete resolution of symptoms, assessed up to 3 months

    Description: Will be compared between treatment groups using log-rank test.

    Measure: Time to hospital admission for those who develop severe of critical symptoms

    Time: From time of randomization to the time of hospital admission, assessed up to 3 months

    Description: Will be compared using Fisher's exact test, and point and interval estimates will be provided.

    Measure: Intensive care unit (ICU) admission: yes or no

    Time: 3 months

    Description: Will be compared using Fisher's exact test, and point and interval estimates will be provided.

    Measure: Receiving ventilator support: yes or no

    Time: 3 months

    Description: Will be compared using Fisher's exact test, and point and interval estimates will be provided.

    Measure: Overall survival

    Time: From randomization to death due to any cause, assessed up to 3 months

    Other Outcomes

    Description: Will be compared between treatments group using t-test or non-parametric comparison if the distribution of lab values are deviated from normal distribution. The proportion of participants of whom lab values are obtained will be tabulated and compared using the chi-square test.

    Measure: Potassium level

    Time: 3 months

    Description: Will be compared between treatments group using t-test or non-parametric comparison if the distribution of lab values are deviated from normal distribution. The proportion of participants of whom lab values are obtained will be tabulated and compared using the chi-square test.

    Measure: Blood oxygen level

    Time: 3 months

    Description: Will be compared between treatments group using t-test or non-parametric comparison if the distribution of lab values are deviated from normal distribution. The proportion of participants of whom lab values are obtained will be tabulated and compared using the chi-square test.

    Measure: Creatinine level

    Time: 3 months

    Description: Will be compared between treatments group using t-test or non-parametric comparison if the distribution of lab values are deviated from normal distribution. The proportion of participants of whom lab values are obtained will be tabulated and compared using the chi-square test.

    Measure: Blood pressure

    Time: 3 months

    Description: Will evaluate on a subjective basis the ability to remotely consent, monitor and treat patients in the context of a pandemic of a contagious disease. The proportion of participants able to be remotely consented, monitored, and treated in the context of a pandemic of a contagious disease will be tabulated and compared using the chi-square test.

    Measure: Ability to remotely consent, monitor, and treat patients in the context of a pandemic of a contagious disease

    Time: 3 months
    18 Remote COVID-19 Symptom Tracking and Improved Cancer Symptom Control for Cancer Patients at Home During the Pandemic

    This project will evaluate the benefit of an automated home symptom monitoring system, Symptom Care at Home, to track COVID-19 symptoms, provide instructions to reduce COVID-19 exposure, and reduce cancer symptom severity during the COVID-19 pandemic. The investigators will determine if Symptom Care at Home decreases the need for cancer patients to use emergency departments and hospitalization for cancer symptom care. The project addresses the urgent public health need for cancer patients to reduce their risk for COVID-19 exposure.

    NCT04464486
    Conditions
    1. Oncology
    Interventions
    1. Other: SCH Intervention
    MeSH:Neoplasms
    HPO:Neoplasm

    Primary Outcomes

    Description: Retrospective chart review of health care utilization of both groups

    Measure: Health Care Utilization Comparison

    Time: 5 months

    Secondary Outcomes

    Description: Patient Reported Outcomes Measurement Information System- Short Form v2.0 Social Isolation- 6a. The PROMIS Social Isolation item bank assesses perceptions of being avoided, excluded, detached, disconnected from, or unknown by, others. The item bank does not use a time frame (e.g. over the past seven days) when assessing social isolation. A higher PROMIS T-score represents more of the concept being measured. For negatively-worded concepts like Social Isolation, a T-score of 60 is one SD worse than average. By comparison, a Social Isolation Tscore of 40 is one SD better than average.

    Measure: Patient Social Isolation

    Time: Monthly for 5 months

    Description: Patient reported outcomes collected in automated SCH system daily of COVID-19 symptoms, social distancing and hygiene practices, and COVID-19 related cancer treatment impacts and daily living impacts on cancer patients receiving the SCH -COVID intervention. The investigators will describe patterns of cancer patients and their adherence to social distancing and hygiene practices over time.

    Measure: COVID-19 Symptoms, Social distancing and Hygiene Practices

    Time: Daily for 5 months

    Description: Patient Reported Outcomes Measurement Information System Scale v1.2- Global Health Survey Short Form 10. High scores reflect better functioning. To find the total raw score for these scales with all questions answered, sum the values of the response to each question for a given respondent.

    Measure: Patient Global Health

    Time: Monthly 5 months

    Description: Hospital Anxiety and Depression Scale (HADS) measurement of psychological distress in non-psychiatric patients.

    Measure: Patient Anxiety/Depression

    Time: Monthly 5 months

    Description: COVID-19: Impact of the Pandemic and Health Related Quality Of Life (HRQOL) in Cancer Patients and Survivors

    Measure: Impact of Pandemic and Health Related Quality of Life

    Time: Baseline then 3 months and 5 months from baseline

    Description: Patient reported outcomes collected in automated SCH system daily of cancer symptom severity on a scale of 0-10 with 0 being no pain and 10 being worst pain imaginable. Description of symptom severity over time will be reported

    Measure: Cancer symptom severity

    Time: Daily for 5 months.
    19 Well-Being and Quality of Life in Cancer Patients and Survivors During the COVID-19 Pandemic

    This study investigates the well-being and health-related quality of life in cancer patients and survivors during the COVID-19 pandemic. Using questionnaires may help researchers gain an understanding of how experiences during the COVID-19 pandemic (e.g., exposure, risk factors, testing, isolation, seropositivity, hospitalization, loss of family or friends, loss of income), may impact multiple domains of health-related quality of life (physical, emotional and social well-being), and other areas such as COVID-19-specific psychological distress (e.g., fear, anxiety and depressive symptoms), and disruptions to health care, finances, and social interactions.

    NCT04500600
    Conditions
    1. COVID-19 Infection
    2. Hemat
    3. Hematopoietic and Lymphoid Cell Neoplasm
    4. Malignant Solid Neoplasm
    Interventions
    1. Other: Quality-of-Life Assessment
    2. Other: Questionnaire Administration
    MeSH:Neoplasms
    HPO:Neoplasm

    Primary Outcomes

    Description: This will be measure with a COVID-19 questionnaire created to collect COVID-19 experience information, Quality of life (QOL), and other psychosocial variables from participating patients. Using this questionnaire may help researchers gain an understanding of how experiences during the COVID-19 pandemic (e.g., exposure, risk factors, testing,isolation,seropositivity, hospitalization, loss of family or friends, loss of income), may impact multiple domains of health-related quality of life (physical, emotional and social well-being), and other areas such as COVID-19-specific psychological distress (e.g., fear, anxiety and depressive symptoms), and disruptions to health care, finances, and social interactions.

    Measure: Experiences during the coronavirus disease 2019 (COVID-19) pandemic

    Time: 2 months

    Description: This will be measure with a COVID-19 questionnaire created to collect COVID-19 experience information, Quality of life (QOL), and other psychosocial variables from participating patients. Using this questionnaire may help researchers gain an understanding of how experiences during the COVID-19 pandemic (e.g., exposure, risk factors, testing,isolation,seropositivity, hospitalization, loss of family or friends, loss of income), may impact multiple domains of health-related quality of life (physical, emotional and social well-being), and other areas such as COVID-19-specific psychological distress (e.g., fear, anxiety and depressive symptoms), and disruptions to health care, finances, and social interactions.

    Measure: COVID-19-specific psychological distress

    Time: Up to 2 months

    Description: This will be measure with a COVID-19 questionnaire created to collect COVID-19 experience information, Quality of life (QOL), and other psychosocial variables from participating patients. Using this questionnaire may help researchers gain an understanding of how experiences during the COVID-19 pandemic (e.g., exposure, risk factors, testing,isolation,seropositivity, hospitalization, loss of family or friends, loss of income), may impact multiple domains of health-related quality of life (physical, emotional and social well-being), and other areas such as COVID-19-specific psychological distress (e.g., fear, anxiety and depressive symptoms), and disruptions to health care, finances, and social interactions.

    Measure: COVID-19-specific health

    Time: Up to 2 months

    Description: This will be measure with a COVID-19 questionnaire created to collect COVID-19 experience information, Quality of life (QOL), and other psychosocial variables from participating patients. Using this questionnaire may help researchers gain an understanding of how experiences during the COVID-19 pandemic (e.g., exposure, risk factors, testing,isolation,seropositivity, hospitalization, loss of family or friends, loss of income), may impact multiple domains of health-related quality of life (physical, emotional and social well-being), and other areas such as COVID-19-specific psychological distress (e.g., fear, anxiety and depressive symptoms), and disruptions to health care, finances, and social interactions.

    Measure: COVID-19-specific financial and social disruptions

    Time: Up to 2 months

    Description: This will be measure with a COVID-19 questionnaire created to collect COVID-19 experience information, Quality of life (QOL), and other psychosocial variables from participating patients. Using this questionnaire may help researchers gain an understanding of how experiences during the COVID-19 pandemic (e.g., exposure, risk factors, testing,isolation,seropositivity, hospitalization, loss of family or friends, loss of income), may impact multiple domains of health-related quality of life (physical, emotional and social well-being), and other areas such as COVID-19-specific psychological distress (e.g., fear, anxiety and depressive symptoms), and disruptions to health care, finances, and social interactions.

    Measure: COVID-19-specific perceived benefits and social support

    Time: Up to 2 months

    Description: This will be measure with a COVID-19 questionnaire created to collect COVID-19 experience information, Quality of life (QOL), and other psychosocial variables from participating patients. Using this questionnaire may help researchers gain an understanding of how experiences during the COVID-19 pandemic (e.g., exposure, risk factors, testing,isolation,seropositivity, hospitalization, loss of family or friends, loss of income), may impact multiple domains of health-related quality of life (physical, emotional and social well-being), and other areas such as COVID-19-specific psychological distress (e.g., fear, anxiety and depressive symptoms), and disruptions to health care, finances, and social interactions.

    Measure: COVID-19-specific health related quality of life (HRQoL)

    Time: Up to 2 months

    Description: Will evaluate the extent to which resiliency factors such as social support and perceived benefits moderate the effects of COVID-19 experiences on COVID-19-specific psychological distress and HRQoL.

    Measure: Effects of COVID-19 experiences on COVID-19-specific psychological distress and HRQoL

    Time: Up to 2 months
    20 A Phase 1/2 Trial of Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy

    This phase I/II trial investigates the best dose and side effects of leflunomide and how well it works in treating patients with COVID-19 and a past or present cancer. Leflunomide has been used since the 1990s as a treatment for rheumatoid arthritis. Experiments done with human cells that were given severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing COVID-19, showed that leflunomide was able to reduce the ability of the virus to make copies of itself. The coronavirus uses ribonucleic acid (RNA), a very long molecule that contains genetic information that is like a blueprint for making more copies of itself. Leflunomide inhibits the formation of RNA. The information gained from this study may help researchers to learn whether leflunomide is safe for use in treating patients with COVID-19, and whether it is potentially effective against the disease.

    NCT04532372
    Conditions
    1. Hematopoietic and Lymphoid Cell Neoplasm
    2. Malignant Solid Neoplasm
    3. Symptomatic COVID-19 Infection Laboratory-Confirmed
    Interventions
    1. Other: Best Practice
    2. Drug: Leflunomide
    3. Drug: Placebo Administration
    MeSH:Laboratory Infection Neoplasms
    HPO:Neoplasm

    Primary Outcomes

    Description: Observed toxicities will be summarized in terms of type (organ affected or laboratory determination), severity, time of onset, duration, probable association with the study of treatment and reversibility or outcome.

    Measure: Incidence of toxicity, graded according to the NCI CTCAE version 5

    Time: Up to 28 days after completion of study treatment

    Description: Will be based on the assessment of dose limiting toxicity (DLT).

    Measure: Maximum tolerated dose (MTD) (Phase 1)

    Time: During the 28-day treatment period

    Description: Defined as a >= 2-point change in clinical status from day 1 on a 7-point ordinal scale.

    Measure: Clinical activity (Response)(Phase 2)

    Time: At day 28

    Secondary Outcomes

    Description: Defined as time from start of treatment to >= 2 point change in clinical status on a 7 point ordinal scale

    Measure: Time to Clinical activity (Response)

    Time: Up to 28 days

    Description: Defined as time from start of treatment to death from any cause

    Measure: Overall Survival

    Time: Up to 90 days

    Description: Time from start of treatment to peripheral capillary oxygen saturation (SpO2) > 93% on room air

    Measure: Oxygen Saturation improvement

    Time: Up to 90 days

    Description: Time from start of treatment to first negative severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) result assessed by polymerase chain reaction (PCR).

    Measure: SARS-CoV-2 resolution

    Time: Up to 90 days

    Description: Hospitalized within first 90 days following start of treatment assessed as yes/no

    Measure: Hospitalization

    Time: Up to 90 days

    Description: Indication as to whether or not the subject required mechanical ventilation at any time from start of treatment through 90 days post; assessed as yes/no

    Measure: Mechanical Ventilation required

    Time: Up to 90 days

    Description: If the subject required mechanical ventilation, indicate number of days for first occurrence; measured in days.

    Measure: Mechanical Ventilation duration

    Time: Up to 90 days

    Description: Vital status will be reported as yes/no

    Measure: Vital status (alive/dead)

    Time: Up to 90 days

    Description: If vital status is dead, cause of death will be documented.

    Measure: Vital status (cause of death)

    Time: Up to 90 days

    Other Outcomes

    Description: Measured by PCR assay of viral ribonucleic acid (RNA) from nasopharyngeal swab.

    Measure: Viral load

    Time: from start of treatment to 90 days
    21 Effect of a Telerehabilitation-exercise Intervention in Oncology Patients in the Covid-19 Pandemic

    The aim is to analyze the feasibility and effect of an online Therapeutic Exercise and Education programme (TEEP) in cancer patient and survivors

    NCT04547634
    Conditions
    1. Cancer Metastatic
    2. Cancer
    3. Survivorship
    Interventions
    1. Other: Therapeutic Exercise and Education
    MeSH:Neoplasms
    HPO:Neoplasm

    Primary Outcomes

    Description: Patients are asked before each session to mark in a numerical scale how are they feeling that day to push themselves and get their session well done. From 0 (very well) to 10 (very badly). Higher scores mean a worse feeling.

    Measure: Suitability of exercise intensity

    Time: Through study completion, an average of 3 months

    Description: Patients are asked to score the feeling of perceived effort after the session with the Borg Perceived Exertion scale (6-20). Higher scores mean a worse perceived exertion.

    Measure: Verification of exercise intensity

    Time: Through study completion, an average of 3 months

    Description: Total of days of attendance

    Measure: Total attendance

    Time: After intervention, an average of 3 months

    Description: Reasons of absence, categorized as: personal matter, visit the oncology, medical appointment (no related to oncology treatment), health problem, connection problem or unknown.

    Measure: Absence type

    Time: Through study completion, an average of 3 months

    Description: Attendance type, categorized as: full attendance, partly attendance because of lack of time, partly attendance because of internet connection problem

    Measure: Attendance type

    Time: Through study completion, an average of 3 months

    Secondary Outcomes

    Description: The Spanish version of the Piper Fatigue Scale-Revised (PFS-R) will be used. Its total score is the sum of all items (from 0 to 220), with higher values indicate a higher level of fatigue (worse outcome)

    Measure: Change from Cancer-Related Fatigue (CRF)

    Time: Prior and after intervention, an average of 3 months

    Description: It will be tested by 30-second Sit-To-Stand Test (30-STS), number of repetitions completed.

    Measure: Change from Functional capacity

    Time: prior and after intervention, an average of 3 months

    Description: the Spanish version of Upper Limb Functional Index (ULFI) questionnaire will be filled online

    Measure: Change from Upper limb functionality (%)

    Time: prior and after intervention, an average of 3 months

    Description: the Spanish version of Lower Limb Functional Index (LLFI) questionnaire will be filled online

    Measure: Change from Lower limb functionality (%)

    Time: prior and after intervention, an average of 3 months

    Description: It will be assessed by The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) version 3.0. EORTC QLQ-C30 comprises 30 items and contains five functional scales, three symptom scales, a global health status/QoL scale, and six single items. Raw scores can be linearly converted to a 0-100 scale with higher scores reflecting higher levels of function (better outcome) and higher levels of symptom show bigger problems (worse outcome).

    Measure: Change from Quality of life (self-reported questionnaire)

    Time: prior and after intervention, an average of 3 months

    Description: It will be assessed by The European Organization for Research and Treatment of Cancer Breast Cancer-Specific Quality of Life questionnaire (EORTC QLQ-BR23). This is a breast cancer module of EORTC QLQ-C30 which contains 23 items that assess disease symptom, side effects of treatment, body image, sexual functioning, and future perspective. All items are rated on a 4-point scale (from 1- not at all, to very much). Higher scores represent better functioning (better outcome), and higher scores of symptom show bigger issues (worse outcome)

    Measure: Change from specific Breast Cancer Quality of life (self-reported questionnaire)

    Time: prior and after intervention, an average of 3 months
    22 Impacts of Coronavirus Disease 2019 (COVID-19) Pandemic on Adolescent and Young Adult (AYA) Cancer Patients and Survivors

    The study investigates how the COVID-19 pandemic has impacted the psychological, financial, physical, and social well-being of adolescent and young adult (AYA) cancer patients and survivors. AYA cancer survivors have inferior long-term survival compared to the general population, and the negative impact of the global COVID-19 pandemic may be even higher in this vulnerable group. The information gained from this study may provide an opportunity to determine the self-reported COVID-19 specific psychological distress in AYA cancer survivors, and may lead to the development of a targeted intervention to improve physical and psychosocial health for AYA cancer patients and survivors.

    NCT04551378
    Conditions
    1. COVID-19 Infection
    2. Hematopoietic and Lymphoid Cell Neoplasm
    3. Malignant Solid Neoplasm
    Interventions
    1. Other: Quality-of-Life Assessment
    2. Other: Survey Administration
    MeSH:Neoplasms
    HPO:Neoplasm

    Primary Outcomes

    Description: Assessed per responses to the 12 questions pertaining to COVID-19 specific psychological stress within the adolescent and young adults (AYA) Cancer Survivor COVID-19 Survey section titled, "COVID-19 Related Distress (Emotional and Physical Reactions) and Health Behaviors.'' This survey includes both a 5-level Likert scale for the respondent's current level of concern (Not at all, A little, Neutral, A lot, Very Much), plus an ordinal 3-level scale for the respondent to rate the perceived level of change compared to before COVID-19 (Less, Same, More). Responses to individual questions will be summarized at each time point as means (for the Likert scale) and percentages (for discrete levels of change), together with 95% confidence intervals. For each question, will also summarize the percentages of patients in each group checking one of the 3 levels (Less, Same, More) indicating whether they perceived a change in that question since before COVID-19.

    Measure: Coronavirus disease 2019 (COVID-19) specific psychological stress

    Time: At baseline, 6 months, and 12 months

    Secondary Outcomes

    Description: Will be summarized by group and time point. Associations between endpoints and demographic, treatment-related and resilience variables, as well as differences among groups will be assessed by t-test, analysis of variance or Chi-square test. Non-parametric tests (Wilcoxon rank sum, Kruskal-Wallis, Fisher's exact) will be employed when appropriate. Regression models (e.g., linear, logistic etc.) will also be employed. Change from baseline to subsequent time points in Likert scores will be modeled by mixed-effect models, while blocking on patient to control for repeated measures. Models will include baseline demographic, treatment-related, and resilience factor variables as covariates.

    Measure: Survey responses

    Time: At baseline, 6 months, and 12 months

    Description: Will be summarized by group and time point. Associations between endpoints and demographic, treatment-related and resilience variables, as well as differences among groups will be assessed by t-test, analysis of variance or Chi-square test. Non-parametric tests (Wilcoxon rank sum, Kruskal-Wallis, Fisher's exact) will be employed when appropriate. Regression models (e.g., linear, logistic etc.) will also be employed. Change from baseline to subsequent time points in Likert scores will be modeled by mixed-effect models, while blocking on patient to control for repeated measures. Models will include baseline demographic, treatment-related, and resilience factor variables as covariates.

    Measure: Patient reported outcomes

    Time: At baseline, 6 months, and 12 months

    Description: Will be summarized by group and time point. Associations between endpoints and demographic, treatment-related and resilience variables, as well as differences among groups will be assessed by t-test, analysis of variance or Chi-square test. Non-parametric tests (Wilcoxon rank sum, Kruskal-Wallis, Fisher's exact) will be employed when appropriate. Regression models (e.g., linear, logistic etc.) will also be employed. Change from baseline to subsequent time points in Likert scores will be modeled by mixed-effect models, while blocking on patient to control for repeated measures. Models will include baseline demographic, treatment-related, and resilience factor variables as covariates.

    Measure: Changes of survey responses

    Time: At baseline, 6 months, and 12 months

    Description: Will be summarized by group and time point. Associations between endpoints and demographic, treatment-related and resilience variables, as well as differences among groups will be assessed by t-test, analysis of variance or Chi-square test. Non-parametric tests (Wilcoxon rank sum, Kruskal-Wallis, Fisher's exact) will be employed when appropriate. Regression models (e.g., linear, logistic etc.) will also be employed. Change from baseline to subsequent time points in Likert scores will be modeled by mixed-effect models, while blocking on patient to control for repeated measures. Models will include baseline demographic, treatment-related, and resilience factor variables as covariates.

    Measure: Changes in discrete responses

    Time: At baseline, 6 months, and 12 months

    Description: Will be separately modeled by logistic regression with relation to group and time point as well as demographic and cancer characteristics in order to assess factors associated with non-response and to assess associated bias. Other statistical approaches might be used as appropriate.

    Measure: Incidence of survey question non-response

    Time: At baseline, 6 months, and 12 months
    23 An onLine-pLatform to Improve Patient-centered Care During the COVID-19 pAndemic: a GIMEMA surveillaNce Program in hematologiC malignanciEs

    This is a national multicenter prospective observational study led by the GIMEMA. The GIMEMA-ALLIANCE Platform is also an online monitoring system for patients with hematologic malignancies aiming at helping hematologists in the early recognition and timely management of problems of their patients. Based on patient's rating of specific items (i.e. on the presence of clinically relevant problems or problems with adherence to therapy or risk of SARS-CoV-2 infection), the Platform will automatically send alerts to the treating hematologist (and/or appointed members of the local Team). Physicians will be free to make any action they feel appropriate for the best care of their patients.

    NCT04581187
    Conditions
    1. Hematologic Malignancies
    Interventions
    1. Other: Quality of life assessment
    MeSH:Neoplasms Hematologic Neoplasms
    HPO:Hematological neoplasm Leukemia Neoplasm

    Primary Outcomes

    Description: To prospectively assess HRQOL in adult patients with hematologic malignancies, overall and by patient subgroups (e.g., by diagnosis of COVID-19)

    Measure: HRQOL in adult patients with hematologic malignancies

    Time: After 2 years from date of registration

    Description: To prospectively assess symptoms in adult patients with hematologic malignancies, overall and by patient subgroups (e.g., by diagnosis of COVID-19)

    Measure: Symptoms in adult patients with hematologic malignancies

    Time: After 2 years from date of registration

    Description: To prospectively assess adherence to therapy in adult patients with hematologic malignancies, overall and by patient subgroups (e.g., by diagnosis of COVID-19)

    Measure: Adherence to therapy in adult patients with hematologic malignancies

    Time: After 2 years from date of registration

    Secondary Outcomes

    Description: To describe the prevalence of clinically relevant functional limitations (e.g., physical and social) and symptoms (e.g., fatigue, pain and dyspnea) by type of hematologic malignancy and by type of treatment (e.g., standard chemotherapy of oral anticancer therapies)

    Measure: Prevalence of clinically relevant functional limitations and symptoms

    Time: After 2 years from date of registration

    Description: To investigate factors associated with physical and mental health concerns

    Measure: Factors associated with physical and mental health concerns

    Time: After 2 years from date of registration

    Description: To examine the financial and social impact imposed by the COVID-19 pandemic on patient health outcomes

    Measure: Financial and social impact imposed by the COVID-19 pandemic on patient health outcomes

    Time: After 2 years from date of registration

    Description: To examine the limitations in accessing routine medical care services imposed by the COVID-19 pandemic on patient health outcomes

    Measure: Limitations in accessing routine medical care services imposed by the COVID-19 pandemic on patient health outcomes

    Time: After 2 years from date of registration

    Description: To describe clinical strategies adopted by physicians in response to patient-generated alerts, across different clinical scenarios

    Measure: Clinical strategies adopted by physicians

    Time: After 2 years from date of registration
    24 Thromboembolic Risk Screening in Patients With Cancer and COVID-19

    Study Rational Since December 2019, outbreak of COVID-19 caused by a novel virus SARS-Cov-2 has spread rapidly around the world and became a pandemic issue. First data report high mortality in severe patients with 30% death rate at 28 days. Exact proportions of the reasons of death are unclear: severe respiratory distress syndrome is mainly reported which can be related to massive cell destruction by the virus, bacterial surinfection, cardiomyopathy or pulmonary embolism. The exact proportion of all these causes is unknown and venous thromboembolism could be a major cause because of the massive inflammation reported during COVID-19. High levels of D-dimers and fibrin degradation products are associated with increased risk of mortality and some authors suggest a possible occurrence of venous thromboembolism (VTE) during COVID-19. Indeed, COVID-19 infected patients are likely at increased risk of VTE. In a multicenter retrospective cohort study from China, elevated D-dimers levels (>1g/L) were strongly associated with in-hospital death, even after multivariable adjustment. Also, interestingly,the prophylactic administration of anticoagulant treatment was associated with decreased mortality in a cohort of 449 patients, with a positive effect in patients with coagulopathy (sepsis-induced coagulopathy score ≥ 4) reducing the 28 days mortality rate (32.8% versus 52.4%, p=0.01). However the presence/prevalence of VTE disease is unknown in COVID-19 cancer patients with either mild or severe disease. Cancer patients are at a higher risk of VTE than general population (x6 times) and could be consequently at a further higher of VTE during COVID-19, in comparison with non-cancer patients. The exact rate of VTE and pulmonary embolism during COVID-19 was never evaluated, especially in cancer patients, and is of importance in order to understand if this disease needs appropriate prophylaxis against VTE. The largest series of cancer patients so far included 28 COVID-19 infected cancer patients: the rate of mortality was 28.6%. 78.6% of them needed oxygen therapy, 35.7% of them mechanical ventilation. Pulmonary embolism was suspected in some patients but not investigated due to the severity of the disease and renal insufficiency, reflecting the lack of data in this situation. The aim of the present study is to analyze the rate of symptomatic/occult VTE in a cohort of patients with cancer. Expected benefits Anticipated benefits of the research are the detection of VTE in order to treat it for the included patient. For all COVID-19 positive cancer patients it will enable to provide some guidelines and determine which patient are at risk for VTE and which will need ultrasound to detect occult VTE. Foreseeable risks Foreseeable risks for patients are non-significant because the additional procedures needed are ultrasound exam, and blood sample test. Methodology Retrospective and prospective (ambispective), multicentric study to evaluate the occurrence of venous thromboembolism during COVID-19 infection. Indeed, because the outbreak can end within the next 3-6 months, Investigators may not be able to answer the question if Investigators only focus on patients investigated prospectively. Investigators then decided to include patients from medical team who are already systemically screening patients with COVID-19 disease for VTE. Trial objectives Main objective To evaluate the rate of venous thromboembolism at 23 days during COVID-19 infection in cancer patients.

    NCT04616846
    Conditions
    1. Neoplasms Malignant
    2. Covid19
    3. Thromboembolism
    Interventions
    1. Diagnostic Test: Peripheral venous ultrasound
    MeSH:Neoplasms Thromboembolism
    HPO:Neoplasm Thromboembolism

    Primary Outcomes

    Description: Deep venous thrombosis and/or pulmonary embolism.

    Measure: Rate of venous thromboembolism

    Time: From Day 9 to Day 42

    Secondary Outcomes

    Description: Rate of hospitalization

    Measure: Hospitalization due to venous thromboembolism

    Time: Day 23

    Description: Time between the date of inclusion and the date of death for any reason.

    Measure: Overall Survival

    Time: Day 23

    Description: Time between the date of inclusion and the date of death for venous thromboembolism.

    Measure: Specific survival

    Time: Day 23

    Description: Common toxicity criteria from the NCI CTCAE V5.0

    Measure: Safety profile using the common toxicity criteria from the NCI CTCAE V5.0

    Time: Day 1 to Day 23

    Description: Khorana score (low risk (score=0), medium risk (score=1 ou 2) and high risk (score ≥ 3)

    Measure: Predictive factors for venous thromboembolism

    Time: Day 1 to Day 23

    Description: Caprini score (very low risk (score=0), low risk (score=1 or 2), medium risk (score=3 or 4)and high risk (score ≥ 5)

    Measure: Predictive factors for venous thromboembolism

    Time: Day 1 to Day 23

    Description: Common toxicity criteria from the NCI CTCAE V5.0

    Measure: rate of symptomatic venous thromboembolism between the COVID-19 negative and COVID-19 positive patients

    Time: Day 1 to Day 23
    25 Expanded Evaluation of the Survivorship Wellness Group Program in the Context of COVID-19 and Telehealth

    This study evaluates the effects of the Survivorship Wellness Group Program following active treatment, as well as to learn from Survivorship Wellness participants about their concerns regarding the current COVID-19 pandemic. This study may help to evaluate the impact of the survivorship program on patient well-being, provide evidence for use in grant application and publications, and ultimately inform the continued improvement of survivorship care.

    NCT04630015
    Conditions
    1. COVID-19 Infection
    2. Hematopoietic and Lymphoid Cell Neoplasm
    3. Malignant Solid Neoplasm
    Interventions
    1. Other: Survey Administration
    MeSH:Neoplasms
    HPO:Neoplasm

    Primary Outcomes

    Description: The PROMIS Anxiety Short form consists of 2 items addressing patient anxiety with item response scores ranging from 1 (never) to 5 (Always). Raw scores are converted to scaled T-scores with higher scores indicating a greater level of anxiety. Significant changes over time and trends in patient reported outcomes will be analyzed via student's T-test.

    Measure: Changes in the Patient Reported Outcome Measurement Information System (PROMIS) Anxiety Short Form over time

    Time: Baseline, Week 9, and Week 15, up to 15 weeks total

    Description: The PROMIS Depression Short form consists of 4 items addressing patient depression with item response scores ranging from 1 (never) to 5 (Always). Raw scores are converted to scaled T-scores with higher scores indicating a greater level of depression. Significant changes over time and trends in patient reported outcomes will be analyzed via student's T-test.

    Measure: Changes in the Patient Reported Outcome Measurement Information System (PROMIS) Depression Short Form over time

    Time: Baseline, Week 9, and Week 15, up to 15 weeks total

    Description: The FACT-G is a 27-item questionnaire designed to measure four domains of health related quality of life (HRQOL) in cancer patients with 4 domains of interest: Physical, social, emotional, and functional well-being. Each tem response score ranges from 0 (not at all) to 5 (very much). The total score is a sum of the subscale scores, with a range from 0 - 108. The higher the score, the better the HRQOL.

    Measure: Changes in the Functional Assessment of Cancer Therapy (FACT-G) scores

    Time: Baseline, Week 9, and Week 15, up to 15 weeks total
    26 Perceptions, Experiences, and Activity in CancEr Survivors During COVID-19

    To examine perceptions and determinants of physical activity during the COVID-19 pandemic among cancer survivors.

    NCT04637295
    Conditions
    1. Neoplasms Malignant
    MeSH:Neoplasms
    HPO:Neoplasm

    Primary Outcomes

    Description: Godin Leisure-Time Exercise Questionnaire

    Measure: Physical Activity

    Time: 14 days

    Description: COVID-19 Pandemic Psychosocial Functioning Measure

    Measure: Psychosocial Function during COVID-19

    Time: 14 days

    Secondary Outcomes

    Description: The Exercise Self-efficacy Scale will be used to measure confidence in ability to exercise. A higher score indicated a higher confidence.

    Measure: Self-Efficacy

    Time: 14 days

    Description: The Pittsburgh Sleep Quality Index will be used to measure sleep quality and disturbances. A higher score indicates a higher sleep disturbance.

    Measure: Sleep Quality

    Time: 14 days

    Description: The Functional Assessment in Chronic Illness Therapy - Fatigue (FACIT-F) will be used to measure fatigue as well. Higher scores indicate less fatigue.

    Measure: Fatigue

    Time: 14 days

    Description: The Hospital Anxiety and Depression Scale (HADS) will be used to produce an anxiety score. Higher scores indicate higher symptoms of anxiety.

    Measure: Anxiety

    Time: 14 days

    Description: The Hospital Anxiety and Depression Scale (HADS) will be used to produce an anxiety score. Higher scores indicate higher symptoms of depression.

    Measure: Depression

    Time: 14 days

    Description: The UCLA Loneliness Scale will be used to measure feelings of loneliness and isolation. Higher scores indicate higher degrees of loneliness.

    Measure: Loneliness

    Time: 14 days

    Description: The Rosenberg Self-Esteem Scale (RSE) will be used to measure global self-esteem. Items are used to calculate an esteem score, higher scores are indicative of higher esteem.

    Measure: Global Self-Esteem

    Time: 14 days

    Description: The Functional Assessment in Cancer Therapy- Cognition (FACT-Cog) measures levels of cognitive impairment, quality of life and perceived cognitive ability. Items are summed up to calculate scores from each subsection.

    Measure: Subjective Cognitive Impairment

    Time: 14 days

    Description: The Social Support of Exercise scale is aimed to assess the degree in which family and friends demonstrate support for exercise behavior. Higher scores indicate a higher level of support.

    Measure: Social Support

    Time: 14 days

    Description: The Satisfaction of Life Scale (SWLS) is developed to assess global satisfaction is various age groups.

    Measure: Satisfaction of Life

    Time: 14 days

    Description: The Perceived Stress Scale is a 10-item scale developed to measure the perceptions of a person's stress.

    Measure: Stress

    Time: 14 days

    Description: A qualitative interview will be performed to measure the perceptions and barriers of exercise during the COVID-19 pandemic. This interview is comprised of items designed by the research team.

    Measure: Perceptions of Exercise

    Time: up to one month after enrollment
    27 Investigation of the Perception of the COVID-19 Pandemic in Patients With Haematological or Solid Neoplasias Using Patient-reported Outcome Measures (PROMs)

    Cancer patients are among the most vulnerable individuals, whose health-related quality of life (HRQOL) may be substantially impacted by the COVID19 pandemic. We want to study how the COVID-19 pandemic influences the life of cancer patients and how these patients cope with the additional distress with the aim to facilitate the development of improved future interventional strategies to maintain resilience and HRQOL

    NCT04649320
    Conditions
    1. Covid19
    Interventions
    1. Other: questionnaire
    MeSH:Neoplasms
    HPO:Neoplasm

    Primary Outcomes

    Description: evaluation via questionnaire

    Measure: Influence of the COVID-19 pandemic on cancer patient's daily life

    Time: single time
    28 COVID-19: Well-Being in Cancer Patients With Neuropathy Who Participated in Prior Clinical Trials

    This study investigates the experiences of cancer patients with neuropathy during the COVID-19 pandemic to learn how the COVID-19 pandemic affects their quality of life and clinical outcomes. This study will also explore whether there are differences between patients who received neurofeedback (NFB, a type of therapy that is thought to help normalize brain activity) and those who did not. Learning about quality of life in cancer patients with neuropathy during the COVID-19 pandemic may help guide development of programs and policies to improve chronic pain patient care and outcomes during a major global healthcare crisis.

    NCT04650178
    Conditions
    1. COVID-19 Infection
    2. Hematopoietic and Lymphoid Cell Neoplasm
    3. Malignant Solid Neoplasm
    4. Neuropathy
    Interventions
    1. Other: Quality-of-Life Assessment
    2. Other: Questionnaire Administration
    MeSH:Neoplasms
    HPO:Neoplasm

    Primary Outcomes

    Description: We will use the COVID-19 Specific questionnaire. This scale will ask 15 questions that are organized into three sections: (a) Questions specific to the COVID-19 pandemic such as testing, serostatus, risk factors, loss of family or friends, isolation; (b) Thoughts, experiences and emotions regarding the COVID-19 pandemic; and (c) Health-related quality of life. This assessment was developed by Lorenzo Cohen (MD Anderson), in collaboration with investigators from the University of Miami and UCLA and is a comprehensive assessment of COVID-19 experiences.

    Measure: Health-related quality of life and coronavirus disease 2019 (COVID-19)-specific domains of interest

    Time: through study completion, an average of 6 months

    Description: Will evaluate bivariate associations between COVID-19 experiences and COVID-19-specific distress, HRQOL and clinical outcomes, using Pearson product-moment correlation coefficients, chi-squared tests, or analyses of variance (ANOVA) where appropriate.

    Measure: COVID-19 experiences and COVID-19 specific distress

    Time: through study completion, an average of 6 months

    Description: Will use linear regression (or generalized linear models, as applicable) to assess differences in the outcomes of interest between neuropathic pain patients who received neurofeedback (NFB) from either of the two NFB trials (principal investigator [PI]: Dr. Prinsloo) and the neuropathic pain patients who participated in Dr. Gibby-Reyes' trial (who, consequently, did not receive NFB).

    Measure: Differences in outcomes between neuropathic pain patients

    Time: through study completion, an average of 6 months

    Description: Will preliminarily test the interaction effect between each of the coping and resilience factors and COVID-19 experiences on COVID-19-specific distress, HRQOL and clinical outcomes.

    Measure: Coping and resilience factors

    Time: through study completion, an average of 6 months
    29 Coping With COVID: The Effect of the COVID-19 Public Health Crisis on Mental Well-Being in Cancer Patients Seen at the Psychiatric Oncology Clinic

    This study determines how the threat of the coronavirus has affected the mental health and physical well-being of cancer patients seen at the psychiatric oncology clinic, and how they have coped with any related stress. Questionnaires that assess coping strategies and behaviors for decreasing disease transmission may help researchers create recommendations for future public health crises and pandemics.

    NCT04652505
    Conditions
    1. COVID-19 Infection
    2. Hematopoietic and Lymphoid Cell Neoplasm
    3. Malignant Solid Neoplasm
    Interventions
    1. Other: Questionnaire Administration
    MeSH:Neoplasms
    HPO:Neoplasm

    Primary Outcomes

    Description: sum score on the Patient Health Questionnaire, a 9-item scale with a sumscore ranging between 0 and 27, with a higher score indicating more-severe depression.

    Measure: Patient-reported severity of depression

    Time: Baseline

    Description: sum score on the generalized anxiety disorder questionnaire, a 7-item scale with sumscore range between 0 and 21. A higher score indicates higher severity of anxiety.

    Measure: Patient-reported severity of anxiety

    Time: Baseline

    Description: score on the National Comprehensive Cancer Network Distress Thermometer, a one-item 0-10 scale. A higher score indicates higher distress.

    Measure: Patient-reported severity of distress

    Time: Baseline

    Secondary Outcomes

    Description: Physical symptoms are assessed with individual-item response on the Edmonton Symptom Assessment Scale by the clinic. The ESAS includes 6 somatic symptom items, each of which is to be rated on a 0-10 scale, with higher scores indicating higher severity of the symptom.

    Measure: Patient-reported physical symptoms

    Time: Baseline

    Description: Substance use is documented by the treating physician and will be abstracted from clinic notes.

    Measure: Substance use

    Time: Baseline

    Description: Assessed using the brief COPE questionnaire. Will examine active versus avoidant coping. Active coping, planning, positive reframing, acceptance, humor, religion, emotional support-seeking, and instrumental support-seeking will be considered active coping strategies. Self-distraction, denial, venting, substance use, behavioral disengagement, and self-blame will be considered maladaptive coping strategies.

    Measure: Patient-reported coping strategy

    Time: Baseline

    Description: The Apathy evaluation Scale is an 18-item scale with a sum score ranging between 18 and 72. A higher scores indicates higher apathy..

    Measure: Patient-reported levels of apathy

    Time: Baseline

    Description: Patients indicate how often during the pandemic they engaged in the following 5 behaviors endorsed by the World Health Organization to decrease the transmission of coronavirus disease 2019 (COVID-19): washing hands regularly for 20 seconds with soap and water or alcohol-based hand rub, covering nose and mouth with a disposable tissue or flexed elbow when you cough or sneeze, avoiding close contact with people who are unwell, staying home and self-isolating from others in the household when feeling unwell, avoiding touching eyes, nose, and mouth when hands are unclean. The behaviors will be assessed on a Likert scale of 1-5, with 1 being "never" and 5 being "always". A not available (N/A) option will be given for staying home and self-isolating from others when feeling unwell, since participants may not experience a period of feeling unwell.

    Measure: Patient-reported engagement in the 5 health behaviors endorsed by World Health Organization intended to curb the spread of the coronavirus

    Time: Baseline

    HPO Nodes


    HP:0002664: Neoplasm
    Genes 1522
    SF3B1 GFI1B IGF2 FIBP RPS7 WT1 COL7A1 TREX1 HSPG2 CASP8 SLC22A18 MC1R TFE3 KRAS PLAG1 OFD1 BRAF NUMA1 KRT16 PSENEN CTPS1 APC SOX9 FANCM OPCML CDKN2A RPS15A CTNNB1 SDHD EDN3 FCN3 NELFA GJC2 MALT1 HPGD GLI1 CD70 SPINK1 LETM1 PMS1 LRP5 HNF1B EXT1 TCF4 ELMO2 MET ANTXR1 KRT16 KRT10 PAX4 SETBP1 TERT WT1 SMARCB1 GJB6 HRAS STK11 BUB1B GNPTAB MYD88 MCC GJB2 BRCA1 TP63 PDGFRL TARS1 NF1 FGFR3 KARS1 BARD1 BRIP1 GATA2 IL1RN BRAF CD81 TNFRSF13B TYROBP AR LIG4 KLF11 ABL1 MVK BMPR1A PIK3CA B3GALT6 SLC37A4 SOS1 TSC1 FGFR3 ATRX FANCG TET2 KIT SRP72 MPL TP53 SMAD4 EVC2 MAPRE2 DLST BRCA1 DICER1 HRAS AKT1 RNR1 TSC1 TNPO3 XRCC4 DNMT3A NEUROD1 THPO MN1 NOD2 SRSF2 PPM1D FLT4 ATP7A IL7 KRAS GDNF WNT10A EPAS1 COL1A1 IL1B MRAP ADAMTS3 PRKCD SUFU PTCH1 ERCC3 KRT14 CXCR4 HOXD13 IGF2 LIG4 PALB2 BLM NRAS ERCC3 FOXP1 SDHD TP53 PKD2 PDX1 TINF2 ADA2 MYF6 RHBDF2 POU6F2 PHKG2 CDKN2A RUNX1 ERCC2 MAP2K2 WT1 USB1 GATA4 FGFR2 ACD CR2 MUTYH ARL6IP6 FAH MSH2 RASA1 NEK1 SOX6 NR0B1 LIG4 CDKN2B NF1 NF1 POLE RPL35 SRY SDHAF2 FANCL CPLX1 FAS PRKAR1A PHB SDHA CALR PIK3R1 FAN1 TET2 TMEM216 RSPO1 SEMA3D MDM4 SDHD HRAS NUP214 GJA1 PIK3CA CCND1 RNF6 MSH2 C11ORF95 MVK MCM4 FLI1 TINF2 KIAA0753 ECM1 ARSA ERCC2 SOX2 SDHC SLC26A2 MPL VANGL1 PUF60 RAD51D POT1 CR2 ESCO2 FOXE1 PMVK SRY GJB4 TRIM37 KIT EXT2 PDGFB KIF1B FANCF IGF2R MLH1 GDNF PIK3CA ASCC1 ASCL1 TCIRG1 APPL1 RPS19 BCL10 IGF2 NRAS FLT3 STAT1 BCL10 RMRP GNAI3 KRAS GPR101 BAP1 NKX2-1 MAX BMPR1A DDB2 SMARCB1 RAD51 FGFR3 ALX4 BTK MSH6 NOTCH3 DICER1 CXCR4 CCBE1 RET WT1 TP53 PALLD RNASEH2B WT1 ATR CCND1 KCNQ1OT1 SMAD4 AHCY STK11 FANCC TRNK BCL6 SMAD4 SKIV2L HMBS TP53 TERT PHOX2B SNAI2 BRAF TCOF1 FANCI NRAS REST SDHC HBB HFE CREBBP MET SEC23A CEP57 CTLA4 TRIM28 SMAD7 GNAS BRCA2 PALB2 FGF8 SBDS RET ALK GJB2 CPLANE1 GPC3 TCTN3 PTEN RB1 INTU CYP26C1 LEMD3 PRLR CDON NLRP1 GPR101 DHH HNF4A MMEL1 DNASE1L3 RASGRP1 ATRX CHEK2 FANCA SPRED1 DNM2 FLT4 CHEK2 RPS19 KLLN HACE1 HNF1A PTPN11 CDKN1B GAS1 BRCA2 KCNQ1OT1 NPM1 FGFR3 MC1R MINPP1 PTPN11 TSC2 ABCA5 BRCA2 PLCB4 SCN11A HNF1A BRAF RB1 CBL ARHGAP26 SUFU PTPRJ C1S APC IRF5 GNAQ GDNF TERT MYSM1 XPC TMC8 COL4A5 ERBB3 SLC26A4 CD96 NSUN2 PDGFRA FERMT1 TYR DNAJC21 MSH2 SH3GL1 TUBB RET BRAF ESR1 PAX3 RHBDF2 RTL1 WRN DYNC2LI1 ELANE EXOC6B RPS26 EWSR1 VHL PIGA GCGR POU6F2 RNF43 POLE BRAF MNX1 SFTPA2 CDH23 ASCL1 APC ACVR1 PIGL BAX RAG2 RSPO1 MSH3 PGM3 FGF3 FANCE MPL TP53 COL7A1 BUB1 TET2 PALB2 ACTB PNP SDHC EDN3 XPA TMC6 NEK1 GNA11 KAT6B KRT1 RUNX1 PAX7 NOTCH1 ENG CTNNB1 ETV6 MPLKIP PARN CDKN2A PTPN3 STAG3 MDM2 TP53 LAMC2 NBEAL2 VAMP7 GNA14 DCLRE1C CBL GCDH FANCC AXIN2 PYGL SOS1 BLK WRAP53 IDH1 KRAS CCM2 APC ASXL1 ATP7B ERCC3 SF3B1 EP300 BRCA2 MGAT2 NRTN CDKN2A DICER1 PMS1 RPS10 TBC1D24 FAH BRCA2 ASXL1 BCR C2CD3 KRAS IDH1 IGLL1 RASA1 BRCA2 CHEK2 PTCH1 RNF113A BRAF MBTPS2 EDNRB IGHM PDGFRB RAF1 MEN1 FASLG TUBB NDUFAF6 FOXI1 TGFBR1 EPCAM CYLD SDHB APC CYP2D6 TAF1 KRT17 BRCA1 BUB1B BAP1 GDF2 BUB1B ERCC2 TP53 KRT5 GATA2 BRCA1 RAD54B MRE11 STAC3 DNMT3A MLH1 BCHE EDN3 CDKN1B AURKA NRAS FLCN IDH2 EDN1 ESCO2 USF3 IGH POT1 ACVRL1 JAK2 NBN NRAS SQSTM1 TMEM127 ZFPM2 SLC12A3 NTHL1 ADA CHIC2 STAT3 SETBP1 FANCB FIBP STAT3 STK11 MLLT10 SFTPC HDAC4 NUP214 GLI2 SLX4 TSC1 ERCC6 TP53 CLCNKB KLF6 OGG1 JAK2 PAX6 RECQL4 RPL31 MYO1H FH RPGRIP1L SLC45A2 RPL10 RPL10 HMBS GDF5 TNFRSF10B PIK3CA GABRD TP53 BRCA2 SEMA4A BCR PALB2 ASXL1 KRT6B CCDC22 SAMD9 DMPK DCC ERCC5 RPL5 CTNNB1 RPS27 TRNS2 PTCH1 PTEN TFAP2A RPS24 RPL35A RET AXIN1 HNF1B ARMC5 UBE2T SRP54 SSX2 DKC1 ERCC3 JAK2 GNA11 LAMB3 GJB2 NFKB1 KCNQ1 GLI3 PIK3CA KANSL1 CASP8 MYC RECQL4 ACAN CACNA1S BDNF KIF11 MDH2 MSL3 FGFR1 TERF2IP HFE NFKB2 TOP2A GFI1 SRD5A3 PHKA2 MAX POLE MAP2K1 EYA1 RNF43 ALX3 SETD2 ERCC4 CTLA4 SIX3 LEMD3 OCRL CDH23 DZIP1L MSH3 AR CDC73 PDGFRL TWIST1 POU2AF1 DKC1 CALR LIN28B KRT6A GATA1 MC1R DIS3L2 CD28 CDC73 ADA2 UROD CIB1 TSR2 WNT5A TET2 PHOX2B BMPER KIT DLC1 MSTO1 H19-ICR SLC25A13 ADAR TMEM67 BMPR1A MLH3 POLR1C KRT6B FH EFL1 TERC BUB3 FOXC2 NOTCH3 KIT NSD1 FGFR2 SLC6A17 MAP3K1 TRIP13 MEG3 RRAS2 BMPR1A NF1 DPM1 LIG4 PARN RHOH BRCA2 NF1 TAF15 RFWD3 VHL H19 BCR KRAS VANGL2 KRAS SDHD DVL3 BIN1 ABL1 GPC3 HAX1 FANCA GDNF NHP2 IGF2 VHL CCL2 EXTL3 RUNX1 PRKCD BLNK MSH6 SLC22A18 IL2RG PTH1R SDHB AIP WDPCP APC KCNJ10 ASPSCR1 OCA2 TP53 WT1 SPRTN TET2 TAL1 L2HGDH KIT SDHC ERCC4 GPR143 PRKN SMAD4 SEMA3C TRNS1 BRCA1 SHOX PCNA FANCG CREB1 TRNH VHL MYLK BAP1 SUFU ANTXR1 POLD1 NODAL IGH JAK2 MS4A1 MEN1 TSC2 GATA2 DHCR7 TINF2 F13B RB1 COL7A1 SCN4A BMPR1A DDB2 CDKN2A SDHD CYP11B2 IL7 ARID1B KIT FGFR1 RET CDKN2A LAMA3 CHEK2 TBX2 TBX18 HNF4A GPC4 SHH LMNA BMP2 YY1 AKT1 WT1 BAP1 FZD2 SH2B3 BTK GATA1 RAD54L ATM CTBP1 PTEN SRY RYR1 CTHRC1 MFN2 PTEN RAD21 PTEN MYC SLC26A2 TP53 CTNNB1 RAD51C NAB2 NLRP1 SUFU DLL1 PSAP SDHB REST TGFBR2 TRIP13 IGH ABCC8 IL6 CPLANE1 H19 FANCD2 FGFR2 RET PKD1 DNMT3A REST CHEK2 GNAQ MXI1 BRIP1 DYNC2LI1 GNAS TP53 GLI3 DIS3L2 NRAS PICALM WT1 BAP1 MEN1 TXNRD2 MGMT PTEN MYD88 GNAS POT1 AGGF1 BUB1 PTEN PORCN HFE NUTM1 PHOX2B MSX2 PMS2 SLX4 H19 USP9X RPL27 GNAS SEC23B CBL CD28 PKHD1 AXIN2 TRPV3 KLLN SSX1 TSC1 PPOX KRT17 CARD14 HRAS TCF3 RPL11 CC2D2A GREM1 CHEK2 AP2S1 NRAS TRNL1 ALX1 CREBBP TCTN3 TET2 ESCO2 DOCK8 NRAS STK11 GCM2 TTC37 WT1 SMAD4 DAXX MITF BCL2 DIS3L2 POLR1D TDGF1 KRAS TNFRSF13C KIT PHOX2B SF3B1 RPL15 NF1 TERT TNFRSF1B FANCD2 MLH3 IL7R GPC4 H19-ICR SLC17A9 MEN1 MST1R KIT RAD50 TJP2 DNAJC21 PDCD10 MUTYH IL12RB1 SH2D1A FGFR2 NBN KRAS KIT CASR ENPP1 SDHB HRAS IKBKG PNP EXT2 BRD4 SMARCB1 REST COL11A2 TG KIT LIG4 SUFU NBN RSPRY1 CYSLTR2 SDHD AAGAB BLM RAG1 RNF139 RB1CC1 ACD PTPN11 SLC26A2 TREX1 BMPR1B DDR2 ZAP70 MNX1 MAGT1 AIP GATA2 AR STAR IFIH1 IDH2 BRCA1 USP8 RB1 FGFRL1 SMO USP8 RMRP SLC25A11 MLH3 FUZ DOCK8 SUFU NF2 KDR KRAS RPS14 CASP10 SRP54 ZSWIM6 TBXT PTCH2 EWSR1 TNFRSF13C MTAP NQO2 RPL18 DNAJC21 GCK ERCC6 KDM6B EXT1 SBDS CCND1 SDHAF2 KCNH1 CYLD LMOD1 PDGFRA CAT CHRNG TRNQ ADA NRAS TLR2 SHOX FGFR3 BCL10 TYR KRAS COL2A1 PTCH2 SMO GBA MSTO1 TREM2 JAK2 TMEM231 MSH2 ASXL1 RET DHCR7 NBN PIK3CA NSD2 SDHB EIF2AK4 PALB2 KIF7 PTPN11 PIK3CA HLA-DRB1 STIM1 TMC6 KIF1B TNFSF15 RELA AKT1 NPM1 APC SDHA SDHB STAT6 CDKN1C CDC73 PTCH2 KANSL1 ZSWIM6 FLCN HBB LZTS1 FN1 TRAF7 ACP5 CTNNB1 MLH1 EXT2 RNASEL RNASEH2A IL2RG ATP7A CDK4 CYP11B1 MMP1 SDHB ATRX ACTG2 FOXH1 OFD1 NEK9 STS MUC5B PRKCD PTPN11 PTCH2 LRRC8A RPL26 MSH6 NNT LZTR1 CDC73 PTEN AKT1 AKT1 SASH1 HRAS ANAPC1 PTPN12 KCNJ11 TCF4 GATA2 MLH3 ERCC4 GNB1 DISP1 IDH1 BCR GANAB MSH6 NR5A1 TSC2 GFI1 TNFSF12 TRNP MAPK1 IFNG FLT4 MTM1 WWOX HABP2 RPS28 HRAS SLCO2A1 ND5 SDHB CHD7 BRIP1 SLC37A4 MC2R XRCC3 TNFRSF4 NAGS PHF21A ZIC2 PCGF2 SMARCE1 CTNNB1 SRP54 CDH1 CDK4 RPS20 KCNJ10 RAD21 RNF6 COL14A1 SMO CD19 WRN SRGAP1 CDKN2C AXIN2 GPC6 WWOX HSPA9 FOXI1 CPOX RPS17 APC2 MYH8 SERPINA1 ATM LMX1B ENG POLH TGFBR2 DHX37 VEGFC KIF1B KRT17 DDX41 SPIB CBFB HRAS BCL10 PIGL FGFR1 NSD1 F5 KCNN3 BAX PIEZO2 RECQL4 CREBBP KIT PDGFB PDE6D ABCA5 AKT1 KLHDC8B TNFSF12 EPCAM RARA MLH1 GINS1 EVC PIK3CA FANCE WIPF1 NF2 PDGFRA PRKAR1A CDH1 SDHD PRCC TRNF PTCH1 TNFRSF1B WNT10A WWOX MAD1L1 MTOR WDPCP RNASEH2C NSD2 SAMD9L FH LPP NF1 KRIT1 NTHL1 IL12A HNF1A CDH1 SMARCB1 SMARCE1 CD19 FH FDPS TRPS1 ERCC4 SMPD1 SMARCD2 BRCA1 MPL CRKL SEC23A EXT1 PERP ATM FOXE1 CDKN2B CTSC SIX1 FAM149B1 CDH1 RAD51C ALX3 DLST TRIP13 ING1 PDGFRB FLT3 COL18A1 MST1 TGIF1 TMEM107 SRSF2 TRIM28 BAP1 ANTXR2 CD79A PIK3R1 MAP3K1 NOP10 PIK3CA POLD1 KDSR CCND1 TP53 TMC8 ALK MAP2K1 CD79B SDHC ECE1 PALLD CTSA PRDM16 IVNS1ABP CALR FLNA GPR101 BRCA2 ERCC2 DYNC2H1 TFAP2A COL2A1 DVL1 TERT APC TERT TEK EXT2 TERC ALX4 OFD1 LMO1 PDGFRB RPS14 DCC RTEL1 INS TSC2 FAM20C MYH11 GPC3 SCN9A SMAD4 RASGRP1 HBB TGFBR2 RERE NDP PLA2G2A TCF4 MAD2L2 SKI AIP HMMR SDHC SNAI2 PIK3CA LMNA PGM3 ABCB11 TAL2 WT1 VHL PIK3CA TCTN3 SAMD9L ICOS GLI3 RB1 SLC25A13 SDHC DCLRE1C GCM2 VANGL1 SIX6 WT1 PMS2 KCNH1 BARD1 H19-ICR GNAS TERT CIB1 B3GALT6 GJB3 ERBB2 SDHA KRAS CDC73 TNFRSF13B TET2 FGFR3 WAS SEC23B TGFBR2 TP53 NF2 SMARCA4 NF2 SLC26A4 ANTXR2 WRAP53 FAS SAMHD1 TP53 TET2 ATP7A PTEN SH3KBP1 CARMIL2 MVD PDGFB ABCC6 G6PC1 TRNK KRAS GPC3 PTEN NF2 JAK2 DMRT3 GNAQ RAD51 GTF2H5 TMEM127 TERT RUNX1 FAT4 AR HABP2 NR4A3 EP300 MINPP1 OFD1 RASA1 DLEC1 BIRC3 AIP CD27 PHOX2B BMPR1A KCNE3 PLCD1 RAD51 KRT1 MSH3 MITF EPHB2 DHCR24 RABL3 KRT17 XRCC2 NRAS ITK VHL BICC1 RECQL4 SMARCAD1 MYCN RET CTC1 PTCH1 JAK2 SRC SDHB PHOX2B AKT1 KEAP1 JAG1 VHL LETM1 NLRP1 MEN1 BRCA2 FLCN C2CD3 RFWD3 XPA APC APC SDHD FOXO1 MAFA WHCR GPC4 MLH1 ICOS CDKN1B MTMR14 KIT DICER1 EP300 ZFHX3 MMP1 PRKAR1A KRT9 F13A1 CTNNB1 MPL INPP5E NF1 DKC1 TERT DLK1 SCN10A STS RPS29 PTEN FLCN LRBA ELANE GTF2E2 ATM PIK3CA GPR35 CYLD RAD51C CDKN1A WT1 DICER1 PIK3CA TERC PIK3CA SLC25A11 GNAS CEBPA ATP6V1B2 RET XPC EXT1 BRCA2 SH2B3 ERCC3 BRCA2 RTEL1 WASHC5 ERCC2 AKT1 KCNAB2 CYLD STK4 POLH ERCC5 CDH1 CEL XIAP MSR1 TP53 TET2 DHH PRKAR1A

    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    HPO Nodes


    HP:0002664: Neoplasm
    Genes 1522
    SF3B1 GFI1B IGF2 FIBP RPS7 WT1 COL7A1 TREX1 HSPG2 CASP8 SLC22A18 MC1R TFE3 KRAS PLAG1 OFD1 BRAF NUMA1 KRT16 PSENEN CTPS1 APC SOX9 FANCM OPCML CDKN2A RPS15A CTNNB1 SDHD EDN3 FCN3 NELFA GJC2 MALT1 HPGD GLI1 CD70 SPINK1 LETM1 PMS1 LRP5 HNF1B EXT1 TCF4 ELMO2 MET ANTXR1 KRT16 KRT10 PAX4 SETBP1 TERT WT1 SMARCB1 GJB6 HRAS STK11 BUB1B GNPTAB MYD88 MCC GJB2 BRCA1 TP63 PDGFRL TARS1 NF1 FGFR3 KARS1 BARD1 BRIP1 GATA2 IL1RN BRAF CD81 TNFRSF13B TYROBP AR LIG4 KLF11 ABL1 MVK BMPR1A PIK3CA B3GALT6 SLC37A4 SOS1 TSC1 FGFR3 ATRX FANCG TET2 KIT SRP72 MPL TP53 SMAD4 EVC2 MAPRE2 DLST BRCA1 DICER1 HRAS AKT1 RNR1 TSC1 TNPO3 XRCC4 DNMT3A NEUROD1 THPO MN1 NOD2 SRSF2 PPM1D FLT4 ATP7A IL7 KRAS GDNF WNT10A EPAS1 COL1A1 IL1B MRAP ADAMTS3 PRKCD SUFU PTCH1 ERCC3 KRT14 CXCR4 HOXD13 IGF2 LIG4 PALB2 BLM NRAS ERCC3 FOXP1 SDHD TP53 PKD2 PDX1 TINF2 ADA2 MYF6 RHBDF2 POU6F2 PHKG2 CDKN2A RUNX1 ERCC2 MAP2K2 WT1 USB1 GATA4 FGFR2 ACD CR2 MUTYH ARL6IP6 FAH MSH2 RASA1 NEK1 SOX6 NR0B1 LIG4 CDKN2B NF1 NF1 POLE RPL35 SRY SDHAF2 FANCL CPLX1 FAS PRKAR1A PHB SDHA CALR PIK3R1 FAN1 TET2 TMEM216 RSPO1 SEMA3D MDM4 SDHD HRAS NUP214 GJA1 PIK3CA CCND1 RNF6 MSH2 C11ORF95 MVK MCM4 FLI1 TINF2 KIAA0753 ECM1 ARSA ERCC2 SOX2 SDHC SLC26A2 MPL VANGL1 PUF60 RAD51D POT1 CR2 ESCO2 FOXE1 PMVK SRY GJB4 TRIM37 KIT EXT2 PDGFB KIF1B FANCF IGF2R MLH1 GDNF PIK3CA ASCC1 ASCL1 TCIRG1 APPL1 RPS19 BCL10 IGF2 NRAS FLT3 STAT1 BCL10 RMRP GNAI3 KRAS GPR101 BAP1 NKX2-1 MAX BMPR1A DDB2 SMARCB1 RAD51 FGFR3 ALX4 BTK MSH6 NOTCH3 DICER1 CXCR4 CCBE1 RET WT1 TP53 PALLD RNASEH2B WT1 ATR CCND1 KCNQ1OT1 SMAD4 AHCY STK11 FANCC TRNK BCL6 SMAD4 SKIV2L HMBS TP53 TERT PHOX2B SNAI2 BRAF TCOF1 FANCI NRAS REST SDHC HBB HFE CREBBP MET SEC23A CEP57 CTLA4 TRIM28 SMAD7 GNAS BRCA2 PALB2 FGF8 SBDS RET ALK GJB2 CPLANE1 GPC3 TCTN3 PTEN RB1 INTU CYP26C1 LEMD3 PRLR CDON NLRP1 GPR101 DHH HNF4A MMEL1 DNASE1L3 RASGRP1 ATRX CHEK2 FANCA SPRED1 DNM2 FLT4 CHEK2 RPS19 KLLN HACE1 HNF1A PTPN11 CDKN1B GAS1 BRCA2 KCNQ1OT1 NPM1 FGFR3 MC1R MINPP1 PTPN11 TSC2 ABCA5 BRCA2 PLCB4 SCN11A HNF1A BRAF RB1 CBL ARHGAP26 SUFU PTPRJ C1S APC IRF5 GNAQ GDNF TERT MYSM1 XPC TMC8 COL4A5 ERBB3 SLC26A4 CD96 NSUN2 PDGFRA FERMT1 TYR DNAJC21 MSH2 SH3GL1 TUBB RET BRAF ESR1 PAX3 RHBDF2 RTL1 WRN DYNC2LI1 ELANE EXOC6B RPS26 EWSR1 VHL PIGA GCGR POU6F2 RNF43 POLE BRAF MNX1 SFTPA2 CDH23 ASCL1 APC ACVR1 PIGL BAX RAG2 RSPO1 MSH3 PGM3 FGF3 FANCE MPL TP53 COL7A1 BUB1 TET2 PALB2 ACTB PNP SDHC EDN3 XPA TMC6 NEK1 GNA11 KAT6B KRT1 RUNX1 PAX7 NOTCH1 ENG CTNNB1 ETV6 MPLKIP PARN CDKN2A PTPN3 STAG3 MDM2 TP53 LAMC2 NBEAL2 VAMP7 GNA14 DCLRE1C CBL GCDH FANCC AXIN2 PYGL SOS1 BLK WRAP53 IDH1 KRAS CCM2 APC ASXL1 ATP7B ERCC3 SF3B1 EP300 BRCA2 MGAT2 NRTN CDKN2A DICER1 PMS1 RPS10 TBC1D24 FAH BRCA2 ASXL1 BCR C2CD3 KRAS IDH1 IGLL1 RASA1 BRCA2 CHEK2 PTCH1 RNF113A BRAF MBTPS2 EDNRB IGHM PDGFRB RAF1 MEN1 FASLG TUBB NDUFAF6 FOXI1 TGFBR1 EPCAM CYLD SDHB APC CYP2D6 TAF1 KRT17 BRCA1 BUB1B BAP1 GDF2 BUB1B ERCC2 TP53 KRT5 GATA2 BRCA1 RAD54B MRE11 STAC3 DNMT3A MLH1 BCHE EDN3 CDKN1B AURKA NRAS FLCN IDH2 EDN1 ESCO2 USF3 IGH POT1 ACVRL1 JAK2 NBN NRAS SQSTM1 TMEM127 ZFPM2 SLC12A3 NTHL1 ADA CHIC2 STAT3 SETBP1 FANCB FIBP STAT3 STK11 MLLT10 SFTPC HDAC4 NUP214 GLI2 SLX4 TSC1 ERCC6 TP53 CLCNKB KLF6 OGG1 JAK2 PAX6 RECQL4 RPL31 MYO1H FH RPGRIP1L SLC45A2 RPL10 RPL10 HMBS GDF5 TNFRSF10B PIK3CA GABRD TP53 BRCA2 SEMA4A BCR PALB2 ASXL1 KRT6B CCDC22 SAMD9 DMPK DCC ERCC5 RPL5 CTNNB1 RPS27 TRNS2 PTCH1 PTEN TFAP2A RPS24 RPL35A RET AXIN1 HNF1B ARMC5 UBE2T SRP54 SSX2 DKC1 ERCC3 JAK2 GNA11 LAMB3 GJB2 NFKB1 KCNQ1 GLI3 PIK3CA KANSL1 CASP8 MYC RECQL4 ACAN CACNA1S BDNF KIF11 MDH2 MSL3 FGFR1 TERF2IP HFE NFKB2 TOP2A GFI1 SRD5A3 PHKA2 MAX POLE MAP2K1 EYA1 RNF43 ALX3 SETD2 ERCC4 CTLA4 SIX3 LEMD3 OCRL CDH23 DZIP1L MSH3 AR CDC73 PDGFRL TWIST1 POU2AF1 DKC1 CALR LIN28B KRT6A GATA1 MC1R DIS3L2 CD28 CDC73 ADA2 UROD CIB1 TSR2 WNT5A TET2 PHOX2B BMPER KIT DLC1 MSTO1 H19-ICR SLC25A13 ADAR TMEM67 BMPR1A MLH3 POLR1C KRT6B FH EFL1 TERC BUB3 FOXC2 NOTCH3 KIT NSD1 FGFR2 SLC6A17 MAP3K1 TRIP13 MEG3 RRAS2 BMPR1A NF1 DPM1 LIG4 PARN RHOH BRCA2 NF1 TAF15 RFWD3 VHL H19 BCR KRAS VANGL2 KRAS SDHD DVL3 BIN1 ABL1 GPC3 HAX1 FANCA GDNF NHP2 IGF2 VHL CCL2 EXTL3 RUNX1 PRKCD BLNK MSH6 SLC22A18 IL2RG PTH1R SDHB AIP WDPCP APC KCNJ10 ASPSCR1 OCA2 TP53 WT1 SPRTN TET2 TAL1 L2HGDH KIT SDHC ERCC4 GPR143 PRKN SMAD4 SEMA3C TRNS1 BRCA1 SHOX PCNA FANCG CREB1 TRNH VHL MYLK BAP1 SUFU ANTXR1 POLD1 NODAL IGH JAK2 MS4A1 MEN1 TSC2 GATA2 DHCR7 TINF2 F13B RB1 COL7A1 SCN4A BMPR1A DDB2 CDKN2A SDHD CYP11B2 IL7 ARID1B KIT FGFR1 RET CDKN2A LAMA3 CHEK2 TBX2 TBX18 HNF4A GPC4 SHH LMNA BMP2 YY1 AKT1 WT1 BAP1 FZD2 SH2B3 BTK GATA1 RAD54L ATM CTBP1 PTEN SRY RYR1 CTHRC1 MFN2 PTEN RAD21 PTEN MYC SLC26A2 TP53 CTNNB1 RAD51C NAB2 NLRP1 SUFU DLL1 PSAP SDHB REST TGFBR2 TRIP13 IGH ABCC8 IL6 CPLANE1 H19 FANCD2 FGFR2 RET PKD1 DNMT3A REST CHEK2 GNAQ MXI1 BRIP1 DYNC2LI1 GNAS TP53 GLI3 DIS3L2 NRAS PICALM WT1 BAP1 MEN1 TXNRD2 MGMT PTEN MYD88 GNAS POT1 AGGF1 BUB1 PTEN PORCN HFE NUTM1 PHOX2B MSX2 PMS2 SLX4 H19 USP9X RPL27 GNAS SEC23B CBL CD28 PKHD1 AXIN2 TRPV3 KLLN SSX1 TSC1 PPOX KRT17 CARD14 HRAS TCF3 RPL11 CC2D2A GREM1 CHEK2 AP2S1 NRAS TRNL1 ALX1 CREBBP TCTN3 TET2 ESCO2 DOCK8 NRAS STK11 GCM2 TTC37 WT1 SMAD4 DAXX MITF BCL2 DIS3L2 POLR1D TDGF1 KRAS TNFRSF13C KIT PHOX2B SF3B1 RPL15 NF1 TERT TNFRSF1B FANCD2 MLH3 IL7R GPC4 H19-ICR SLC17A9 MEN1 MST1R KIT RAD50 TJP2 DNAJC21 PDCD10 MUTYH IL12RB1 SH2D1A FGFR2 NBN KRAS KIT CASR ENPP1 SDHB HRAS IKBKG PNP EXT2 BRD4 SMARCB1 REST COL11A2 TG KIT LIG4 SUFU NBN RSPRY1 CYSLTR2 SDHD AAGAB BLM RAG1 RNF139 RB1CC1 ACD PTPN11 SLC26A2 TREX1 BMPR1B DDR2 ZAP70 MNX1 MAGT1 AIP GATA2 AR STAR IFIH1 IDH2 BRCA1 USP8 RB1 FGFRL1 SMO USP8 RMRP SLC25A11 MLH3 FUZ DOCK8 SUFU NF2 KDR KRAS RPS14 CASP10 SRP54 ZSWIM6 TBXT PTCH2 EWSR1 TNFRSF13C MTAP NQO2 RPL18 DNAJC21 GCK ERCC6 KDM6B EXT1 SBDS CCND1 SDHAF2 KCNH1 CYLD LMOD1 PDGFRA CAT CHRNG TRNQ ADA NRAS TLR2 SHOX FGFR3 BCL10 TYR KRAS COL2A1 PTCH2 SMO GBA MSTO1 TREM2 JAK2 TMEM231 MSH2 ASXL1 RET DHCR7 NBN PIK3CA NSD2 SDHB EIF2AK4 PALB2 KIF7 PTPN11 PIK3CA HLA-DRB1 STIM1 TMC6 KIF1B TNFSF15 RELA AKT1 NPM1 APC SDHA SDHB STAT6 CDKN1C CDC73 PTCH2 KANSL1 ZSWIM6 FLCN HBB LZTS1 FN1 TRAF7 ACP5 CTNNB1 MLH1 EXT2 RNASEL RNASEH2A IL2RG ATP7A CDK4 CYP11B1 MMP1 SDHB ATRX ACTG2 FOXH1 OFD1 NEK9 STS MUC5B PRKCD PTPN11 PTCH2 LRRC8A RPL26 MSH6 NNT LZTR1 CDC73 PTEN AKT1 AKT1 SASH1 HRAS ANAPC1 PTPN12 KCNJ11 TCF4 GATA2 MLH3 ERCC4 GNB1 DISP1 IDH1 BCR GANAB MSH6 NR5A1 TSC2 GFI1 TNFSF12 TRNP MAPK1 IFNG FLT4 MTM1 WWOX HABP2 RPS28 HRAS SLCO2A1 ND5 SDHB CHD7 BRIP1 SLC37A4 MC2R XRCC3 TNFRSF4 NAGS PHF21A ZIC2 PCGF2 SMARCE1 CTNNB1 SRP54 CDH1 CDK4 RPS20 KCNJ10 RAD21 RNF6 COL14A1 SMO CD19 WRN SRGAP1 CDKN2C AXIN2 GPC6 WWOX HSPA9 FOXI1 CPOX RPS17 APC2 MYH8 SERPINA1 ATM LMX1B ENG POLH TGFBR2 DHX37 VEGFC KIF1B KRT17 DDX41 SPIB CBFB HRAS BCL10 PIGL FGFR1 NSD1 F5 KCNN3 BAX PIEZO2 RECQL4 CREBBP KIT PDGFB PDE6D ABCA5 AKT1 KLHDC8B TNFSF12 EPCAM RARA MLH1 GINS1 EVC PIK3CA FANCE WIPF1 NF2 PDGFRA PRKAR1A CDH1 SDHD PRCC TRNF PTCH1 TNFRSF1B WNT10A WWOX MAD1L1 MTOR WDPCP RNASEH2C NSD2 SAMD9L FH LPP NF1 KRIT1 NTHL1 IL12A HNF1A CDH1 SMARCB1 SMARCE1 CD19 FH FDPS TRPS1 ERCC4 SMPD1 SMARCD2 BRCA1 MPL CRKL SEC23A EXT1 PERP ATM FOXE1 CDKN2B CTSC SIX1 FAM149B1 CDH1 RAD51C ALX3 DLST TRIP13 ING1 PDGFRB FLT3 COL18A1 MST1 TGIF1 TMEM107 SRSF2 TRIM28 BAP1 ANTXR2 CD79A PIK3R1 MAP3K1 NOP10 PIK3CA POLD1 KDSR CCND1 TP53 TMC8 ALK MAP2K1 CD79B SDHC ECE1 PALLD CTSA PRDM16 IVNS1ABP CALR FLNA GPR101 BRCA2 ERCC2 DYNC2H1 TFAP2A COL2A1 DVL1 TERT APC TERT TEK EXT2 TERC ALX4 OFD1 LMO1 PDGFRB RPS14 DCC RTEL1 INS TSC2 FAM20C MYH11 GPC3 SCN9A SMAD4 RASGRP1 HBB TGFBR2 RERE NDP PLA2G2A TCF4 MAD2L2 SKI AIP HMMR SDHC SNAI2 PIK3CA LMNA PGM3 ABCB11 TAL2 WT1 VHL PIK3CA TCTN3 SAMD9L ICOS GLI3 RB1 SLC25A13 SDHC DCLRE1C GCM2 VANGL1 SIX6 WT1 PMS2 KCNH1 BARD1 H19-ICR GNAS TERT CIB1 B3GALT6 GJB3 ERBB2 SDHA KRAS CDC73 TNFRSF13B TET2 FGFR3 WAS SEC23B TGFBR2 TP53 NF2 SMARCA4 NF2 SLC26A4 ANTXR2 WRAP53 FAS SAMHD1 TP53 TET2 ATP7A PTEN SH3KBP1 CARMIL2 MVD PDGFB ABCC6 G6PC1 TRNK KRAS GPC3 PTEN NF2 JAK2 DMRT3 GNAQ RAD51 GTF2H5 TMEM127 TERT RUNX1 FAT4 AR HABP2 NR4A3 EP300 MINPP1 OFD1 RASA1 DLEC1 BIRC3 AIP CD27 PHOX2B BMPR1A KCNE3 PLCD1 RAD51 KRT1 MSH3 MITF EPHB2 DHCR24 RABL3 KRT17 XRCC2 NRAS ITK VHL BICC1 RECQL4 SMARCAD1 MYCN RET CTC1 PTCH1 JAK2 SRC SDHB PHOX2B AKT1 KEAP1 JAG1 VHL LETM1 NLRP1 MEN1 BRCA2 FLCN C2CD3 RFWD3 XPA APC APC SDHD FOXO1 MAFA WHCR GPC4 MLH1 ICOS CDKN1B MTMR14 KIT DICER1 EP300 ZFHX3 MMP1 PRKAR1A KRT9 F13A1 CTNNB1 MPL INPP5E NF1 DKC1 TERT DLK1 SCN10A STS RPS29 PTEN FLCN LRBA ELANE GTF2E2 ATM PIK3CA GPR35 CYLD RAD51C CDKN1A WT1 DICER1 PIK3CA TERC PIK3CA SLC25A11 GNAS CEBPA ATP6V1B2 RET XPC EXT1 BRCA2 SH2B3 ERCC3 BRCA2 RTEL1 WASHC5 ERCC2 AKT1 KCNAB2 CYLD STK4 POLH ERCC5 CDH1 CEL XIAP MSR1 TP53 TET2 DHH PRKAR1A

    Reports

    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook